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There’s three ways to do things, the right way, the wrong way 
and the way that I do it. (Robert De Niro, Casino) 
 
Be an optimist, at least until they start moving animals in 
pairs to Cape Kennedy. (Anonymous) 
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1. P-C compounds - a short introduction 
 
Phosphorus is an essential nutrient due to its varied functions in metabolic pathways and as 
a component of macromolecules such as phospholipids, RNA or DNA. It accounts for about 
3% of the dry weight of all living organisms and plays a vital role in marine ecosystems where 
growth and productivity of organisms is limited by the availability of nitrogen, iron and 
phosphorus.1,2,3 
In the biosphere, phosphorus is present mostly in its highest oxidation state (+5) as inorganic 
orthophosphate (Pi), phosphate-containing minerals and organic phosphate esters.
2 Though, 
over the past decades it has become obvious that other types of organo-phosphorus 
compounds in lower oxidation states also play important roles in biochemistry. Figure 1.1 
(the first digit gives the number of the chapter; the same is true for Schemes) gives an 
overview of the oxidation states of phosphorus in some families of compounds.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phosphonates and phosphinates are characterized by direct, covalent phosphorus to carbon 
bonds (P-C in phosphonates and C-P-C in phosphinates) instead of the carbon-oxygen-
phosphorus (C-O-P) bond which is present in organic phosphate esters.4  
 
Figure 1.1. Oxidation states of phosphorus.4 
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One of their major characteristics is the high chemical stability of the P-C bond in 
comparison to the rather labile and reactive O-P bond. P-C compounds are resistant towards 
hydrolysis under strong acidic and basic conditions at high temperatures, as well as towards 
photolysis, thermal decomposition and the action of phosphatases.5 
Although the dissociation energy of a P-C bond is of the same order of magnitude as those 
for N-P, S-P and  O-P bonds (about 60 kcal/mol), it is much more stable. This is due to the 
much higher activation energy for P-C bond cleavage.6 Phosphonates with substituents on 
their α-carbon atom are an exception from the rule and can be hydrolysed more easily.7 
 
Aminomethylphosphonic acid was the first synthetic organophosphonate to be synthesised 
in 1944. However, it was not until 1959 that the first organophosphonate of biogenic origin, 
2-aminoethylphosphonic acid (2-AEP, 1.1) was isolated from sheep rumen protozoa (Figure 
1.2).8 Since then the number of known natural phosphonates has been steadily increasing 
but is still limited.  
Phosphonates are widely distributed in nature and they account for about 20% of the bio-
available phosphorus in marine ecosystems.9 Many lower organisms produce a large variety 
of phosphonates and phosphinates. They are produced by aquatic and some terrestrial 
invertebrates, as well as by some insects, mollusks and microorganisms where they are 
found as conjugates with macromolecules (associated with glycolipids, glycoproteins or 
polysaccharides). Furthermore, they were identified as a component of phosphonoglycan10, 
a major integral part of the cell wall of Trypanosoma cruzi, which is the pathogen of Chagas 
disease. Phosphonates also play a role as cell protection mechanisms if present in outer-
membrane structures as they are very stable towards enzymatic degradation. In addition to 
that they are believed to be involved in certain invertebrate parasite-host recognition 
mechanisms and to play a role in primitive neuronal systems. In some organisms , such as 
the sea anemone Tealia feline or in the eggs of the snail Helisoma phosphonates account for 
50 and 95% of the total phosphorus content, respectively.3 As macro molecule associates 
they have mainly structural functions. 
 
In addition to those macromolecules, there is also a group of small bioactive molecules of 
secondary metabolic origin (in most cases microbial) which exhibit antibiotic, antimalarial 
and  herbicidal activity and are therefore of special interest. Phosphonates were also found 
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in higher organisms, including human-beings, but they are believed to have dietary origins in 
the latter.11 
 
It is speculated that phosphonates and phosphinates, aka P-C compounds, were the 
dominant phosphorus containing species in the reducing atmosphere of primitive times and 
that they replaced phosphates in early life forms.12 
Nowadays, both biogenic and synthetic organophosphonates can be found. Even though 
industry did not see the potential of phosphonates and phosphinates until recently, there is 
now a wide range of applications for P-C compounds.  
 
As phosphonates are very stable, nearly isosteric to the more labile phosphates and also due 
to their similarity to carboxylic acids, they have a high potential as antimetabolites by 
blocking enzymatic processes.4 Among the most important biogenic phosphonates are 2-AEP 
(1.1), the first phosphonate to be isolated from a natural source; fosfomycin (1.2), showing 
antibiotic activities; phosphinotricin (1.3), a non-selective herbicide, and fosmidomycin (1.4) 
which is an antimalarial agent (Figure 1.2).  
 
 
The favourable properties of phosphonates of natural origin also led to the development of a 
huge number of synthetic organophosphonates. They are used as herbicides, insecticides, 
antiviral agents (phosphonoformate) and flame retardants. Prominent synthetic 
phosphonates are glyphosate (1.5), one of the most widely applied herbicides, and 
alendronate, an anti-osteoporisis agent (1.6) (Figure 1.3).  
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A high amount of these synthetic phosphonates is released into the environment and 
therefore the understanding of their mineralisation is of crucial interest.3 A closer insight 
into antibiotic resistance mechanisms is another reason to investigate phosphonic acid 
biodegradative pathways.  
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2. Some natural P-C compounds of interest 
 
2.1 2-Aminoethylphosphonic acid (2-AEP) 
 
2-AEP is the most abundant organophosphonate and was hence the first one to be isolated 
from a natural source, namely protozoa of sheep rumen.8 Subsequently, 2-AEP was found in 
many other organisms and it was shown to be a head group of membrane lipids like 
phosphatidylethanolamine.4 
These findings led to the discovery of phosphonolipids in many other species, such as 
coelenterates, gastropods, bivalves, bacteria and plants. 
2-AEP is also the most abundant phosphonate species comprised in phosphonoglycans, even 
though N-methylated AEP and different organophosphonates were isolated. 
As 2-AEP biosynthesis does not take place in humans but in some pathogens, it is a 
promising candidate for enzyme inhibition based drugs.4 
 
2.2 Fosfomycin  
 
2.2.1 General remarks 
 
Fosfomycin (1.2) is the first phosphonate antibiotic isolated from Streptomyces fradiae. 
Afterwards, it was isolated from several other strains of Streptomyces. It is effective against 
Gram-positive as well as against Gram-negative bacteria.13 The laboratory-synthesis of 
enantiomerically pure fosfomycin was accomplished in 198914 and since then fosfomycin has 
been used as an intravenously administered antibiotic. It is used in case of β-lactam 
antibiotic intolerance, but its application is limited to the clinical use (due to the intravenous 
administration). 
 
2.2.2 Mode of action 
 
Fosfomycin inhibits phosphoenolpyruvate: UDP-N-acetyl-glucosamine-3-O-
enolpyruvyltransferase (pyruvyl transferase)15, the first enzyme catalysing peptidoglycan 
synthesis and therefore inhibits cell wall biosynthesis of bacteria.16 This enzyme links the 
general nucleotide-sugar metabolism with the synthesis of N-acetylmuramyl peptide. It 
catalyses the reaction of UDP-N-acetylglucosamine (UDP-GlcNAc) and phosphoenolpyruvate 
(PEP) to form an UDP-GlcNAc-3-enolpyruvyl ether. This intermediate is then converted to  
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UDP-N-acetylmuramic acid via reduction. Afterwards, a peptide chain is linked to the 
carboxyl group of the latter and the cell walls of bacteria are formed from these fragments. 
Fosfomycin blocks this reaction by covalently binding to the enzyme pyruvyl transferase. 
However, covalent binding of fosfomycin is only possible in the presence of UDP-GlcNAc. The 
latter is needed as a stabilizer for enzyme/substrate binding between fosfomycin and 
pyruvyl transferase without covalently reacting with either compound at first. 
The antibacterial activity of fosfomycin arises from its structural similarity to PEP. In the 
active site of pyruvyl tranferase, fosfomycin is oriented so that a proton donor activates the 
epoxide. This group normally protonates C-3 in the actual substrate PEP. However, with 
 
Scheme 2.1. Schematic drawing for inactivation of enzyme by fosfomycin (left) compared 
to the reaction of the enzyme with PEP (right); U stands for UDPNGlcNAc.15  
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fosfomycin instead of the natural substrate in the active site, this protonation allows the 
opening of the epoxide by nucleophilic attack of an SH-group of a cysteine residue at C-2 of 
the antibiotic. This leads to the formation of a covalent bond between the enzyme and 
fosfomycin. This irreversible binding inactivates the enzyme (Scheme 2.1). 
 
It is important to note that fosfomycin only acts as a structural analogue of PEP concerning 
this particular enzyme. This arises from the fact that fosfomycin and PEP are not similar in 
the configuration, but in the sensitivity of the C-2-O bond towards addition of a nucleophile 
in the active site of the enzyme. Fosfomycin does not have a carboxyl group responsible for 
strong electrostatic interactions of PEP with other enzymes. Thus, fosfomycin does not 
resemble PEP sufficiently to act as an inhibitor of other enzymes that use PEP as a substrate 
(such as pyruvate kinase, enolase or PEP carboxykinase). Furthermore, these enzymes all 
cleave O-P bonds by their catalytic activity which is not possible in fosfomycin. Therefore, it 
is not able to act either as a competitive inhibitor or by covalent reaction with these 
enzymes. This is the reason why fosfomycin does not have any effect on higher organisms 
such as mammals even though PEP is a ubiquitous primary metabolite.15 
 
2.3 Phosphaisoserine  
 
2.3.1 General remarks 
 
The optically active phosphaisoserine (2.1), 2-amino-1-hydroxyethylphosphonic acid, is the 
phosphonic acid analogue of the non-proteinogenic amino acid isoserine (Figure 2.1). It is a 
 
component of the lipophosphonoglycan in the plasma membrane of the protozoon 
Acanthamoeba castellanii.17 
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2.4 Phosphinothricin 
 
2.4.1 General remarks 
 
2-Amino-4-[hydroxy(methyl)phosphoryl]butanoic acid, phosphinothricin (1.3), is produced 
by Streptomyces viridochromogenes and S. hygroscopicus as a tripeptide bound to the amino 
group of alanylalanine. This tripeptide is called bialaphos and used as herbicide. 
Phosphinothricin has a very low antibiotic potential as it is a structural analogue of 
glutamate (2.2) and therefore its effect can easily be suppressed by the latter. However, it is 
a very potent28 but unselective herbicide, often used in combination with transgenic 
economic plants like corn. 
Possessing a C-P-C structural element, the non-proteinogenic amino acid phosphinothricin is 
special among the natural P-C compounds as it has two phosphorus-to-carbon bonds. 
Expectedly, the biosynthesis of this substance differs from those for other P-C compounds 
and is quite complicated. It involves about 20 steps.4 
 
2.4.2 Mode of action 
 
Plants need glutamine synthase to keep the concentration of toxic ammonia low. 
Phosphinothricin efficiently inhibits the formation of glutamine catalysed by glutamine 
synthase. During glutamine synthesis, the natural substrate of glutamine synthase, 
glutamate (2.2), is phosphorylated by ATP in the first step to give the tetrahedral 
intermediate 2.3 which is converted to glutamine (2.4) in the second step (Scheme 2.2).  
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 Scheme 2.2. Mechanism of glutamate synthase deactivation (right hand side) compared to 
mechanism of glutamine synthesis by the enzyme (left hand side). 
 
Phosphinothricin (1.3) is likewise phosphorylated to give compound 2.5 able to mimick the 
tetrahedral reaction intermediate and thus blockating the enzyme (Scheme 2.2). As the 
phosphorylated product of phophinothricin, produced by the plant itself, and not 
phosphinothricin itself is the active species, its mode of action as herbicide is referred to as 
“Trojan horse” mechanism.4  
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2.5 Fosmidomycin  
 
2.5.1 General remarks 
 
Fosmidomycin (1.4) is an antimalarial drug which was originally isolated as a natural 
antibiotic from Streptomyces lavendulae in 1980.18 Its antimalarial activity was not detected 
until 1998.19 One of its major advantages is the very low toxicity and high activity against 
multiresistent strains of malaria pathogens.20 Disadvantages are its low bioavailability (about 
30%) and the low plasma half-life (about 2.5 h) because of the extremely hydrophilic 
properties. It is tested in combination with other antimalarial agents because of its high 
relapse rate when used as the only therapeutic agent.21 Furthermore, derivates and 
analogues of the natural product are tested.19 
 
2.5.2 Mode of action 
 
Malaria is caused by protozoal parasites called Plasmodia. Four genera are known to infect 
humans, P. falciparum being one of those.19 Isoprenoids in these organisms are not 
biosynthesised by the mevalonate, but Rhomer pathway (nonmevalonate pathway) starting 
from glycerine-aldehyde-3-phosphate (2.6, GA3P) and pyruvic acid (2.7). This pathway is 
found in several genera of bacteria, green algae and in chloroplasts of higher plants (Scheme 
2.3).  
 
The mode of action of fosmidomycin uses this difference between humans and Plasmodia in 
producing isoprenoides. It inhibits 1-deoxy-D-xylulose 5-phosphate (DXP) 
reductoisomerase22, a key enzyme of the Rhomer pathway and therefore blocks the 
parasite’s ability to produce vital isoprenoids. DXP reductoisomerase catalyses the 
isomerisation and reduction of DXP to 2-C-methyl-D-erythritol 4-phosphate (2.8, MEP). 
Scheme 2.4 shows the inhibition of this enzyme by fosmidomycin.  
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Scheme 2.3. First steps of Rhomer pathway. 
 
 
  
Scheme 2.4. Inhibition of DXP reductoisomerase by fosmidomycin; M2+ can either be Mg2+ or 
Mn2+. 
 
It was suggested that although fosmidomycin binds to the active site of this enzyme with a 
comparatively low affinity, it induces structural changes of the enzyme which increase the  
enzyme’s affinity for the agent. Therefore this phosphonate is a very effective competitive 
inhibitor of DXP reductoisomerase. 
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3. Synthetic phosphonates 
 
The field of application for synthetic phosphonates is vast. They are used in agriculture 
because of their herbicidal (glyphosate) and fungicidal activity. They are used in medicine as 
antiviral agents (phosphonoacetic acid) and as diphosphonates having an effect on 
osteoporosis. Furthermore, industry takes advantage of organophosphonates as flame 
retardants, detergent additives and catalysts.11 
 
Phosphonoacetic acid or Fosfonet, for example, is a synthetic antiviral agent. Its natural 
occurrence could not be confirmed yet, but it is quite likely that it is produced by 
microorganisms possessing transaminases but no P-C cleaving enzymes. In such 
microorganisms, phosphonoacetic acid is likely formed as a degradation product of 2-AEP. 
Formation of phosphonoacetic acid could accompany phosphonoacetaldehyde (PAA) 
detoxification in those microbes.3 
 
3.1 Glyphosate  
 
3.1.1 General remarks 
 
Glyphosate (1.5) is probably the most important synthetic organophosphonate. It was first 
produced as an herbicide by Monsanto under the commercial name “Roundup” in 1974. It is 
used all over the world today. It has a very low toxicity (LD50 (rats) > 5g/kg) and is not 
harmful to mammals.23 
 
3.1.2 Mode of action 
 
Glyphosate is a non-selective total herbicide, which blocks the shikimic acid pathway by 
inhibiting the 5-enol-pyruvyl-shikimate-3-phosphate synthase (EPSPS). It is a transition state 
analogue of PEP, the natural substrate of this enzyme. EPSPS catalyses the reaction of 
shikimate-3-phosphate to chorismate, which is a key intermediate for the biosynthesis of 
aromatic amino acids. Therefore, glyphosate blocks the biosynthesis of phenylalanine, 
tyrosine and tryptophan and phenylpropanoids in plants. Resistance mechanisms are 
known.23 It is used with transgenic plants such as soybeans, canola and corn. 
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4. Biosynthesis of P-C compounds 
 
Up to now the biosynthesis of only three biogenic phosphonates has been unravelled in 
detail. These are 2-AEP, fosfomycin and in part bialaphos (a tripeptide containing 
phosphinothricin and two molecules of alanine) numbers, then you don’t need explanation. 
It is assumed that the first step of the biosynthesis of all natural products containing a P-C 
bond is the rearrangement of phosphoenolpyruvate (4.1, PEP) to phosphonopyruvic acid 
(4.2) (Scheme 4.1). This rearrangement was first suggested in 1969.24  
 
Scheme 4.1. First steps of phosphonate biosynthesis, which are postulated to be similar for 
all members of this substance family. 
 
PEP, a ubiquitous primary metabolite, is rearranged to phosphonopyruvic acid (4.2, PnPy) via 
an intramolecular phosphoryl transfer from the oxygen to the carbon atom. The catalysing 
enzyme is called phosphoenolpyruvate phosphomutase (PEPPM).25,26 This reaction probably 
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involves a covalent phosphoenzyme species, which has not yet been identified, and 2-
oxopropanoic acid enolate as intermediates.27  
A common point in phosphonate biosynthesis is the highly unfavourable first step. PnPy has 
to be metabolised immediately after its formation as the reaction equilibrium for its 
formation lies 500-fold at the side of PEP.  
The formed PnPy species is in most cases immediately decarboxylated by PnPy 
decarboxylase to give phosphonoacetaldehyde (4.3, PAA).28 This trimeric enzyme is thiamine 
pyrophosphate and Mg2+ dependent.25,29 
All phosphonate biosynthetic pathways comprise reactions similar to the ones used in 
primary metabolism. For example some steps of bialaphos biosynthesis are quite similar to 
glycolysis and some steps of FR900098 and bialaphos biosynthesis resemble the tricarboxylic 
acid cycle (TCA-cycle). Similarities between P-C compounds and their carboxylic analogues 
partly allow their conversion via the “normal” enzymes, however, enzymes specialized on 
phosphonates have evolved.4 All phosphonates are derived from phosphonoacetaldehyde.  
Of course, there are exceptions to the rule. In the biosynthesis of the fosmidomycin 
analogue FR900098, a condensation reaction between PnPy and acetyl-SCoA accounts for 
the necessary exergonic second reaction step via acetyl-SCoA hydrolysis instead of a 
decarboxylation reaction.4  
 
4.1 Biosynthesis of 2-AEP 
 
The biosynthesis of 2-AEP only requires three enzymes which have already been 
characterized from different species. There is no known organism, from which all three 
proteins have been isolated.29  
Early in vivo P-labeling experiments led to the conclusion, that 2-AEP is derived from 
phosphoenolpyruvate (PEP). However, this could only be confirmed by the isolation of the 
respective enzyme in 1988 and following in vitro studies.30,31 
The first enzyme in the biosynthetic pathway leading to 2-AEP was shown to be 
phosphoenolpyruvate mutase (PEP mutase or PEP phosphomutase). It catalyses the 
transformation of PEP to phosphonopyruvic acid via an intramolecular phosphoryl transfer. 
The equilibrium of this reaction is clearly on the side of PEP. As retention of stereochemistry 
at the phosphorus atom was observed, a mechanism involving a phosphoenzyme 
intermediate was proposed. This intermediate would be formed with inversion of 
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configuration and the following attack of enolpyruvate would again give an inversion leading 
to a net retention of configuration for the overall reaction. This mechanism could not yet be 
confirmed and others were proposed. For example, a dissociative process generating 
metaphosphate, which is kept in place by active site residues of the enzyme, as an 
intermediate, which could account for the same stereochemical outcome.32  
Phosphonopyruvic acid has to be used immediately after its formation as already mentioned 
in the general chapter on phosphonate biosynthesis. Therefore PAA is formed via 
decarboxylation. 
The last required enzyme is an aminotransferase, which up to now has not been 
characterized from 2-AEP producing organisms, but only from 2-AEP degrading ones. It is 
called AEP-transaminase and is a member of the family of PLP-dependant enzymes.4 
 
4.2 Biosynthesis of fosfomycin 
 
The first two steps of the biosynthesis of fosfomycin and 2-AEP are the same. The 
assumption that all phosphonates are derived from PEP is equally true for fosfomycin. The 
methyl group of fosfomycin was originally thought to be directly transferred to PAA from 
methylcobalamine (MeCbl).33 This mechanism would have involved a formal methyl anion, 
which is in contrast to the generally presumed transfer of the methyl group of MeCbl as a 
methyl cation. More recent studies, which are consistent with all former experiments, 
suggest that PAA (4.3) is reduced to hydroxyethylphosphonic acid (4.4, HEP) prior to 
methylation (Scheme 4.2).34  
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The enzyme performing the reduction (PAA reductase) of PAA was identified as an FeIII-
dependent alcohol dehydrogenase needing NADPH as a cosubstrate. 
The methyl transfer to HEP is proposed to involve S-adenosylmethionine (SAM) and a 
reduced [4Fe-4S]-cluster. These two components may be involved in the formation of an 
adenosyl radical (by one electron transfer from the iron-sulfur cluster to SAM) able to 
abstract the pro-(R)-hydrogen atom from C-2 of HEP. This is in agreement with the 
mechanism of other MeCbl dependent enzymes. The generated HEP radical can easily be 
methylated by MeCbl with transfer of a methyl radical to give 2-hydroxypropylphosphonic 
acid (4.5).4,35 
The last step of fosfomycin biosynthesis is the formation of the epoxide ring. This reaction is 
catalysed by a very unusual mononuclear nonheme iron (II) monoxygenase36 which requires 
NADH/H+, 37 molecular O2 and a reductase (the biological one has not yet been identified). 
Unlike most enzymes of this type, there is no α-ketoglutarate dependence. It is called 
hydroxypropylphosphonic acid (HPP) epoxidase and is a homotetramer with one iron atom 
per unit.38 18O-Labeling studies revealed that the oxirane oxygen atom is not derived from 
atmospheric dioxygen.39 However, 18O-labeling of HPP (4.5) yielded labeled fosfomycin as a 
 
Scheme 4.2. Fosfomycin biosynthesis. 
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product. This led to the conclusion that the epoxide ring in fosfomycin is formed in a unique 
way via dehydrogenation of the secondary alcohol HPP.4 
The two mechanisms proposed for this reaction differ in the exact moment for the electron 
transfer reaction, but both include radical substrate intermediates (Scheme 4.3). The 
configuration at C-1 is inverted during formation of the C-O bond. 
 
 
Scheme 4.3. Suggested radical mechanisms for HPP epoxidase, the last enzyme in 
fosfomycin biosynthesis.40 
 
The substrate binding in the active site of the enzyme occurs via both the hydroxyl and the 
PO3
2- groups of HPP. This bidentate coordination induces a conformational change of the 
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enzyme leading to a kind of “closing” of the active site. This was suggested to protect 
reactive species which are formed as intermediates during the reaction.4  
 
4.3 Biosynthesis of phosphaisoserine 
 
Phosphaisoserine is produced by Acanthamoeba castellanii via hydroxylation of 2-AEP. 
Insertion of oxygen into a C-H bond at C-1 by a monoxygenase could be demonstrated with 
labeling experiments. Whether this insertion takes place before or after integration of AEP 
into the lipophosphonoglycan remains elusive. 41 This was the first example of a hydroxylase 
with a P-C compound as its natural substrate. The hydrogen atom abstracted during the 
course of this reaction could be identified as the pro-(S)-hydrogen atom by D-labeling. As 1-
hydroxy-AEP has (R)-configuration17, the insertion takes place with retention of 
configuration.42 The unknown hydroxylase was suggested to be a cytochrome P450 
monooxygense. Enzymes of this type are known to perform insertions of oxygen atoms into 
C-H bonds with retention of configuration and a weak primary kinetic isotopic effect (as can 
be found for phosphaisoserine).17,41 
 
4.4 Biosynthesis of phosphinothricin 
 
The research concerning the biosynthesis of this compound mainly focused on the formation 
of the P-C bonds. Some interesting steps will be discussed in this section. The whole 
biosynthetic pathway summarised in Scheme 4.4 can be found in the literature.4,16  
As already discussed in the general section about the biosynthesis of phosphonates, the first 
two steps of phosphinothricin formation involve the rearrangement of PEP to PnPy (4.2) 
followed by decarboxylation to give phosphonoacetaldehyde (4.3) (Scheme 4.4). These 
common reactions are followed by the reduction of PAA to 2-hydroxyethylphosphonic acid 
(4.4). HEP is afterwards converted to hydroxymethylphosphonate (4.6, HMP) by an enzyme 
called HEP dioxygenase (HEPD), a mononuclear non-heme iron (II) enzyme.43 Since no 
reductact is needed for this reaction, it is safe to assume that all four electrons needed for 
the reduction of one O2-molecule stem from HEP. Experiments showed that carbon atom C-2 
is eliminated as formate.  
Two mechanisms have been proposed for this conversion (Scheme 4.5). A P-C bond is 
cleaved here instead of the C-C bond in PEP rearrangement.4 
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HMP is afterwards oxidized in two steps to the corresponding carboxylic acid 
phosphonoformate (4.7) by a NAD(P)+ dependent alcohol dehydrogenase. However, the 
respective enzyme has not been identified yet. 
Scheme 4.4. Overview of phosphinothricin biosynthesis. 
 
This is followed by a transformation to carboxyphosphoenolpyruvate which is subsequently 
converted to phosphinopyruvate (4.8) in a reaction catalysed by CPEP mutase. This 
rearrangment follows a similar mechanism as the conversion of PEP to PnPy catalysed by 
PEP mutase. CPEP mutase catalyses the deacarboxylation and yields phosphinopyruvate.  
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Scheme 4.5. Suggested mechanisms for the elimination of a CH2 group to form HMP as a 
substrate.4 
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In the next steps of bialaphos biosynthesis, 4-(hydroxyhydrophosphoryl)-2-oxobutanoic acid, 
which is subsequently transaminated to demethylphosphinothricin, is generated (4.9, 
DMPT). Acetylation in this case is a self-protection mechanism of phosphinothricin producing 
organisms against its toxic metabolic product. The methyl group is transferred from MeCbl 
to the N-acetylated form of the tripeptide. This suggestion was underpinned by the fact that 
microorganisms grown without cobalt as trace element accumulated DMPT (4.9) as well as 
the corresponding tripeptide. Labeling studies with 14CH3-cobalamine led to the same 
result.16 
 
Two mechanisms have been proposed for the methyl transfer. The first one involves a 
formal CH3
+ transfer CoI in cobalamine (Scheme 4.6). This species could afterwards be re-
methylated by a methyl donor. It is the simplest possible mechanism for this methyl tranfer.4 
The second mechanism involves radicals and needs an Fe-S cluster as well as S-
adenosylmethionine (SAM) as cofactors.16  
 
 
 
 
 
Scheme 4.6. Proposed mechanism for methyl transfer from MeCbl to DMPT.
4
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4.5 Biosynthesis of FR900098 
 
FR900098 (4.11) belongs to the same group of 3-(N-hydroxyamino)propylphosphonic acids 
as fosmidomycin (1.4) (Figure 4.1).  
 
 
It is produced by Streptomyces lavendulae and exhibits antimalarial activity. As the 
biosynthesis of fosmidomycin still has to be elucidated, the biosynthetic pathway suggested 
for FR900098, which is currently investigated, is presented here instead.26 It is assumed that 
the biosynthetic pathways leading to these two compounds will show similarities. 
 
The first step of FR900098 biosynthesis, according to the above stated general mechanism, is 
the rearrangement of PEP to phosphonopyruvate (4.2). However, the following step is not 
catalyzed by a decarboxylase as in the case of other natural phosphonates. Instead, genes 
encoding enzymes known from the tricarboxylic acid (TCA) cycle were found in the 
FR900098 gene cluster. A homolog of homocitrate synthase accounts for the needed 
exergonic step by catalysing the condensation of PnPy with acetyl-SCoA to form 2-
phosphonomethylmalate (4.12) (Scheme 4.7).  
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This transformation could be proved in vivo.26 Dicarboxylate 4.12 is then converted to the 
isomer 4.13. Subsequently, this intermediate is assumed to be oxidized and decarboxylated 
to give 2-oxo-4-phosphonobutyrate (4.14) in reactions analogous to the ones of the TCA 
cycle. Transamination by a yet unknown enzyme gives -amino acid 4.15 which is 
decarboxylated to -aminophosphonic acid 4.16. This amine is acetylated and hydroxylated 
in vitro to give FR900098 (4.11), though the exact mechanisms of these steps remain to be 
unravelled.4 
  
 
  
Scheme 4.7. Proposed biosynthesis of FR900098. 
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5. Biodegradation of phosphonates - general remarks 
 
5.1 P-C bond cleavage - phosphonates as phosphorus source 
 
Up to now, the biosynthetic pathways leading to the formation of P-C compounds have not 
been studied in detail except for some substances of industrial or medicinal importance. 
However, some general conclusions on the basis of comparative studies can already be 
drawn and similarities between the biodegradation of certain compounds have already been 
determined.  
In contrast to that, very little is known about the mineralisation of phosphonic acid 
derivates. This knowledge is nevertheless important for our comprehension of the natural P-
cycle and the fate of millions of tons of phosphonates released each year into the 
environment by agriculture and industry. A detailed knowledge about the biological 
pathways by which phosphonates are consumed and degraded in nature will provide us with 
new insights into resistence phenomena against herbicides, antibiotics and other agents. 
The first proof for the use of phosphonates as phosphorus source of living organisms was the 
growth of E. coli on alkylphosphonic acids such as methyl- or ethylphosphonic acid which 
was reported in 1963.44 
Although Pi is the preferred phosphorus source of living organisms, bacteria have developed 
pathways to metabolise phosphonates and hence use them as an additional or alternative 
phosphorus source. 
So far, three mechanisms for phosphonate metabolism are known. There are two pathways 
for bacteria using phosphonates as a phosphorus source only. These two metabolic routes 
are called “phosphonatase” and “P-C lyase” pathway.45 They are both regulated via the so-
called pho-regulon and are only relevant in case of Pi starvation. The third biodegradative 
way allows the use of phosphonates as P, C and N sources and is independent of the 
phosphate concentration. Interestingly, this pathway is not regulated via the pho-regulon. 
Numerous earlier studies have suggested that phosphonate breakdown is under the strict 
control of the pho-regulon and P-C compounds can therefore only be used as a phosphorus 
source.46 Later studies revealed that there are metabolic pathways for phosphonate 
breakdown found in some bacterial strains such as Pseudomonas fluorescens 23F 47, 
Rhizobium huakuii PMY148 or Burkholderia cepacia 49 that are independent of the phosphate 
level.  
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5.2 The pho regulon 
 
There is a certain number of genes that are expressed in bacteria in the case of phosphate 
starvation. These genes are also expressed in an environment where phosphate is present, 
but their expression is upregulated drastically (up to 1500-fold), if the environmental 
phosphate level is low. The total of these genes, also called psi genes (phosphate starvation 
inducible genes), comprise the so called pho-regulon.  
The expression of this gene set is feedback regulated by the level of available Pi. The 
regulation is controlled by a signalling cascade. First, the environmental phosphorus is taken 
up by a phosphorus transport system. If Pi is the phosphorus source, it is taken up either by 
the high or the low affinity phosphate transporter. Then phosphate is incorporated into ATP 
inside the cell. If the extracellular phosphate concentration falls below 4 µmol/L, a protein, 
called PhoR (located on the cell surface membrane), autophosphorylates using ATP as a 
phosphate source. PhoR is called the Pi sensor of this signal transduction pathway. It also 
accounts for Pi repression if there is excess phosphate. 
Activated PhoR has kinase activity and subsequently phosphorylates the regulatory protein 
PhoB which, when phosphorylated, activates the transcription of the psi genes. 
Phosphorylated PhoB binds to the promoter region, the so called pho box, of the pho 
regulon and therewith starts the transcription. Such a signalling cascade has been observed 
in several microorganisms such as E.coli, P. aeruginosa, B. subtilis and Klebsiella pneumoniae. 
Similar pathways could be observed in Rhizobium meliloti, Mycobacterium leprae and 
Agrobacterium tumefaciens.2,7 
If there is excess phosphate available, whether originating from an external source or 
produced by P-C bond cleavage, the psi genes are downregulated and hence phosphonates 
can only be used as a phosphorus source in situations of phosphate starvation. Therefore, 
microorganisms metabolising phosphonates under the control of the pho regulon cannot use 
it as a carbon source because the production of phosphate due to P-C bond cleavage inhibits 
further breakdown of phosphonate.25,7 
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5.3 Three pathways  
 
5.3.1 Phosphonatase pathway 
 
The phosphonatase-pathway has very narrow substrate specificity - it acts only on AEP. The 
first step of this pathway involves a transamination reaction of 2-AEP using pyruvic acid as an 
acceptor of the amino group to give phosphonoacetaldehyde (4.3) (Scheme 5.1).25 
Therefore, 2-AEP can be used as a nitrogen source in this pathway. This first step is followed 
by the formation of an imine between a lysine residue in the active site of the enzyme and 
the generated aldehyde. This destabilizes the P-C bond by an electron withdrawing effect 
and thus allows for its formal hydrolysis. It was shown that this fission takes place with net 
retention of configuration at the P atom and yields Pi and acetaldehyde (5.1).
50 
The enzyme catalysing this step is called phosphonoacetaldehyde phosphonohydrolase or 
phosphonatase in short.  
Scheme 5.1. Phosphonate breakdown via the phosphonatase pathway.2 
 
Microorganisms use phosphonates as a sole phosphorus source via this pho-regulon 
controlled pathway and not as a carbon or energy source. The bacterial strain Pseudomonas 
putida NG2 is the only known exception where 2-AEP breakdown via the phosphonatase 
pathway is not regulated via the pho regulon, but is directly dependent on the presence of 
the substrate. The corresponding enzymes have been isolated for example from Bacillus 
cerus, Enterobacter aerogenes, Salmonella typhimurium and Pseudomonas aeruginosa.7 
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5.3.2 P-C lyase pathway 
 
The characteristics of this pathway are a direct dephosphonation (via a redox process) and 
very broad substrate specificity. It acts on substituted as well as on unsubstituted 
phosphonates and is the most widespread pathway for phosphonate degradation in 
bacteria.2 P-C bond cleavage via this mechanism leads to racemisation at the carbon atom. 
As P-C lyase activity could not yet be detected in vitro, the mechanism on the molecular level 
is still unknown. It was suggested that direct P-C bond fission by a so-called P-C lyase will 
give the corresponding hydrocarbon and phosphite, which is subsequently oxidised to give 
orthophosphate (Scheme 5.2). This assumption is underpinned by the fact that mutants 
lacking the ability to metabolise phosphonates equally lose the ability to assimilate 
phosphite.51 Furthermore, this lack of in vitro P-C lyase activity was assigned to the fact that 
at least one component of the responsible enzyme complex is membrane bound, which is 
common for redox enzymes.  
 
 
Scheme 5.2. Phosphonate breakdown via the P-C lyase pathway.2 
 
In vivo studies revealed that the hydrocarbon fragment generated by this cleavage 
mechanism to be the hydrocarbon directly derived from the phosphonate. The formed 
phosphorus species has not yet been identified as the release of Pi in cell-free systems could 
not yet be detected. This can have two reasons: either the produced phosphate is consumed 
directly and converted into another phosphorus species, or the primary phosphorus species 
is not Pi.
7 
Genes for this pathway have been found in E.coli52, Enterobacter aerogenes45 and Rhizobium 
meliloti53 to name a few. So far, no substrates of biogenic origin are known for this pathway 
with the exception of 2-AEP (1.1), which is also a substrate of the phosphonatase-pathway.7 
It was suggested that the function of this pathway may originally be the generation of 
ribose-phosphonate esters, which are products of the degradation cycle of phosphonates.3 
This route is under the control of the pho regulon too. 
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Originally only one type of P-C lyases was postulated, but the suggestion that a variety of 
enzymes of this type exists could be confirmed by in silico analysis. It was revealed by the 
fact that there are significant differences between the gene clusters of P-C lyases in different 
prokaryotes.54 
 
5.3.3 Phosphonopyruvate - and phosphonoacetate hydrolase pathways 
 
If P-C cleavage of xenobiotic phosphonates (phosphonates of synthetic origin) only occured 
by P-C lyases, manmade phosphonates would pose an enormous problem. Their 
biodegradation would be blocked by the suppression of their mineralisation by ubiquitous 
Pi.
3 
The third pathway for phosphonate degradation is different from the two earlier discussed 
routes regarding two facts: it is independent of the phosphate status of the cell and it is 
substrate-inducible. Therefore, the discovery of this pathway broke with the general rule of 
phosphonate breakdown being dependent on phosphate starvation. Hence, microorganisms 
can use phosphonates as carbon and phosphorus source via this pathway. In the case of 
Pseudomonas fluorescens 23F and Burkholderia cepacia Pa16 it could be shown that 
substrate uptake is not suppressed by the release of inorganic phosphate due to P-C bond 
hydrolysis. Also, the use of fosfomycin as a phosphorus and carbon source by Rhizobium 
huakuii PMY1 was observed.46 These strains do not show feedback inhibition25 and can use 
organophosphonates as carbon and energy, rather than phosphorus source. However, both 
fission products, the carbon and the phosphorus containing one, can be used by the 
organism as a nutrient.55 
There are two enzymes known catalysing pho-regulon idependent pathways. The first, 
phosphonopyruvate hydrolase, cleaves phosphonopyruvic acid (4.2) to give Pi and pyruvic 
acid (5.2) in the breakdown of phosphonoalanine, a component of cell membranes in many, 
especially marine, organisms. Burkholderia sp. can use the L-enantiomer of phosphoalanine 
as a C and P source (Scheme 5.3).  
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Scheme 5.3. Phosphonate breakdown via pho-regulon independent pathways.2 
 
The second, phosphonoacetate hydrolase from Pseudomonas fluorescens 23F degrades 
phosphonoacetate (5.3) to give Pi and acetate (5.4). 
2 
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6. Details on the biodegradation of some P-C compounds 
 
6.1 Biodegradation of 2-AEP 
 
The first stept in 2-AEP biodegradation is transamination of the latter to give PAA. The latter 
is then cleaved to give inorganic phosphate and acetaldehyde. These two steps are catalysed 
by two enzymes, called 2-AEP:pyruvate aminotransferase and phosphonoacetaldehyde 
hydrolase (phosphonatase), respectively. The second enzyme has been studied from several 
bacterial strains including Bacillus, Pseudomonas, Enterobacter and Salmonella strains. This 
degradative pathway is under control of the pho-regulon. However, a pho independent 
degradation has been discovered in Pseudomonas putida.46 Mechanistically, an active site 
lysine forms a Schiff’s base intermediate with PAA that leads to a destabilisation of the P-C 
bond and subsequent bond cleavage.  
 
6.2 Biodegradation of fosfomycin 
 
The bacterium Rhizobium huakuii PMY1 is able to use fosfomycin as a phosphorus source 
independent of the phosphate status of the cell and not under control of the pho-regulon. 
Other members of the Rhizobiaceae family have been shown to be capable of metabolising 
synthetic phosphonates like glyphosate. However, the mineralisation was under the strict 
control of the pho-regulon and therefore restricted to the use of organophosphonates as a 
phosphorus source. Use of fosfomycin as carbon, energy and phosphorus source by these 
microorganisms has first been reported in 1998.56 Cleavage of its P-C bond is possibly 
responsible for the resistance to fosfomycin as an antibiotic. Consequently, elucidation of 
the biodegradative pathway of fosfomycin is interesting. As Rhizobiaceae can be found 
everywhere in the biosphere, they may contribute to the rapid detoxification of glyphosate 
and other herbicides of the organophosphonate type. It has not been possible yet to 
demonstrate in vitro P-C bond cleavage activity by cell-extracts from these 
microorganisms.56 This failure is attributed to the fact that the responsible enzyme system is 
membrane bound.  
To elucidate the stepwise biodegradation of fosfomycin, putative intermediates of the 
enzymatic metabolism were synthesized. It was planned to investigate whether they support 
growth of R. huakuii PMY1 or released Pi in cell-extracts in the case of phosphonates. 
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Previous experiments revealed the first step of fosfomycin breakdown not to be the P-C 
bond cleavage, but a modification of the carbon skeleton. Direct P-C bond cleavage would 
result in inorganic phosphate and (S)-methyloxirane which was not considered a suitable 
compound for testing as it is very volatile (bp 35 °C). However, the oxirane could be 
hydrolysed by an enzyme in the cells and hence 1,2-propanediol was tested as a metabolite. 
Neither the racemate nor the (R)-enantiomer supported growth of R. huakuii PMY1. 
However, 1,2-dihydroxypropylphosphonic acid (6.1) which would result from the epoxide 
ring opening before P-C bond cleavage supported growth (Scheme 6.1). 
 
 
Scheme 6.1. Proposed mechanism for epoxide hydrolase acting on fosfomycin as substrate. 
 
As only the (1R,2R)-stereoisomer and none of the three others was metabolised by R. 
huakuii PMY1, the first step of fosfomycin biodegradation was suggested to be epoxide 
hydrolysis.  
Only formal attack of a water molecule at C-2 would invert the configuration and would  give 
the (1R,2R)-1,2-dihydroxypropylphosphonic acid since fosfomycin has (1R,2S)-configuration. 
So far, the crystal structures of three epoxide hydrolases from three different organisms 
have been obtained. As their active sites are quite similar, they are believed to act in the 
same way on their substrates. Two tyrosine residues activate the epoxide by forming 
hydrogen bonds to the oxygen atom reminiscent of acidic hydrolysis. The attacking 
nucleophile is the CO2
- group of an active site aspartate, forming an enzyme bound ester 
with the substrate. This intermediate is hydrolysed by attack of a water molecule to give the 
(1R,2R)-diol. The water molecule itself is activated by a catalytic diade, involving aspartate 
and histidine.57 Attack of OH- at the carbonyl group of the ester releases the diol. 
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However, nucleophilic attack at C-1 would result in the (1S,2S)-enantiomer. Interestingly, 
FosX proteins from M. loti and Listeria catalyze the metal ion assisted ring opening of 
fosfomycin by water at C-1, giving the (1S,2S)-diol, as a genomic encoded mechanism of 
resistance.58 
These results also lead to the conclusion that the second step of the pathway cannot be P-C 
bond cleavage either, because this would again produce 1,2-propanediol which is not 
metabolised. So, another side chain modification has to follow. Suggestions involved 
dehydration at either C-1 or C-2 to give the corresponding oxo-propylphosphonic acids or 
dehydrogenation on either position to give hydroxy-oxopropylphosphonic acids. However, α-
hydroxyalkyl- and α-oxoalkylphosphonates show decreased stability of the P-C bonds 
towards basic hydrolysis. The former give the corresponding aldehydes and phosphite 
whereas the latter give carboxylic acids and again phosphite. R. huakuii PMY1 cannot use 
phosphite as a phosphorus source. Neither direct use nor phosphite oxidase activity could be 
detected. Therefore, these two possibilities had to be discarded too.46 
R. huakuii grows well on hydroxyacetone (6.4) and lactic acid, but not on acetone. Therefore, 
oxidation of the hydroxyl group at C-2 to give 1-hydroxy-2-oxopropylphosphonic acid (6.2) 
was believed to be the next step in fosfomycin metabolism (Scheme 6.2). This putative 
intermediate was synthesized as a racemate. Unfortunately, it was not metabolised by R. 
huakuii PMY1 but released Pi in a cell-extract. To account for the fact that hydroxyacetone is 
readily degraded by R. huakuii PMY1, two possibilities were considered. Either the 2-
oxopropylphosphonic acid did not enter the cells when supplied in the growth medium, or 
the (S)-enantiomer inhibited the degradation of the (R)-enantiomer, which is more likely to 
be the natural product.46 
Furthermore, it was assumed that hydroxyacetone generated from 1-hydroxy-2-
oxopropylphosphonic acid via P-C bond cleavage is oxidized to pyruvic acid. This acid may 
then be incorporated into amino acids. To test this assumption [C-1-13C]-labeled (1R*,2R*)-
1,2-dihydroxypropylphosphonic acid was synthesized. Feeding experiments showed a high 
incorporation rate for this compound into the amino acids alanine (6.5) and valine (6.6), 
isolated from the cell hydrolysate unsing HPLC and investigated by NMR spectroscopy. This 
result was taken as evidence that the P-C bond of 1-hydroxy-2-oxo-propylphosphonic acid 
(6.2) is split.  
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It could also be shown that the C3-fragment stays intact as long as it is attached to 
phosphorus. Hence the carbon fragment released has to contain three carbon atoms. 
However, their substitution pattern is still unknown.  
The cleavage of the P-C bond itself could show similarity to the biodegradation of 2-AEP. 
There, PAA is formed via transamination and subsequently the P-C bond is cleaved. The 
  
Scheme 6.2. Proposed pathway of fosfomycin biodegradation. 
 
catalysing enzyme for the second step is a phosphonatase with a side chain lysine residue in 
its active site which is essential for the catalytic cycle. The amino group of lysine forms 
iminium cation 6.3 with the carbonyl group of ketone 6.2, facilitating P-C bond cleavage by 
attack of an enzyme nucleophile (or less likely a water molecule) at the P atom. The 
protonated Schiff base has an electron sink at C-2 that accepts the electrons of the P-C bond. 
After bond fission the enzyme bound intermediates, the enamine and the phosphorylated 
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enzyme, are hydrolysed, finally producing acetaldehyde and inorganic phosphate, 
respectively. 
Alternatively, an active site metal ion, for example Zn2+, could catalyse the cleavage of the P-
C bond. This could lead to the formation of a metal-complexed enolate, which would be an 
equally good leaving group and hence promote P-C bond cleavage. These two mechanisms 
are proposed by drawing parallels between P-C bond cleavage and C-3-C-4 bond cleavage in 
fructose-1,6-bisphosphate by aldolases in the glycolytic cycle. They are grouped into two 
types on the basis of their catalytic sites, involving either a lysine (and thus an enamine as 
leaving group) or a Zn2+ ion (and therefore an enolate as leaving group).59,60 Furthermore, P-
C bond fission mechanisms involving radicals have also to be taken into account. They could 
proceed via a phosphoryl radical, which could undergo fragmentation to an alkyl radical and 
metaphosphate. The radical could subsequently be converted to the corresponding alkane 
by transfer of an electron and a proton (or an equivalent thereof) and metaphosphate. The 
latter will give Pi by addition of water.
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6.3 Biodegradation of synthetic phosphonates 
 
Glyphosate is not toxic to the environment because of rapid binding to soil and microbial 
degradation.25 The most important degradation product is aminomethylphosphonic acid 
(AMPA) which leads to the conclusion that the first step of mineralisation of glyphosate is C-
N bond cleavage via an enamine species.25 This has been studied with bacteria isolated from 
waste water containing glyphosate. Hydrolysis of the C-N bond gives glyoxylate, which can 
be used by the malate synthase and AMPA synthase. The enzyme catalysing this first 
degradative step is called glyphosate oxidoreductase, a flavoprotein functioning under 
aerobic and anaerobic conditions. 
Another biodegradative pathway for glyphosate used by most bacteria involves initial P-C 
bond cleavage.25 The fission products are Pi and sarcosine (N-methylglycine).
62  
In general, the breakdown of synthetic phosphonates is effected by P-C lyases (see chapter 
5.3.2). A variety of microorganisms can cleave P-C bonds of a broad spectrum of synthetic 
alkyl- and arylphosphonates. However, only little is known about the exact mechanisms of 
their detoxification and their fate in the global phosphorus cycle. 
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7. Applied strategies  
 
7.1 Influences of fluorine on enzymatic processes 
 
7.1.1 Properties of fluorine 
 
The van der Waals radius of fluorine is 1.47 Å. This lies between the values for hydrogen (1.2 
Å) and oxygen (1.57 Å).63 However, replacing a hydroxyl group by a fluorine atom is often 
less tolerated by enzymes than replacing it by a hydrogen atom.  
Oxygen and fluorine are very similar in size, but the electronic effects of both atoms are very 
different. Electrostatic interactions of fluorine are weaker than those exhibited by oxygen. 
Therefore the hydrogen bonding ability of a fluoro-substituted enzyme substrate is reduced 
compared to the natural substrate. As hydrogen bonds and other electrostatic interactions 
are of crucial importance for enzyme/substrate interactions, fluorine is often not able to 
mimic hydroxyl groups properly.64 
However, replacing the smaller hydrogen atom by a fluorine atom is often tolerated well and 
does not have an influence on substrate/enzyme binding. Fluorine is bioisosteric to 
hydrogen.65 X-Ray studies revealed that there is only little distortion in the packing of 
monofluoro-substituted stearic acids.66  
Furthermore, fluorine is the most electronegative element. This is also an important 
criterion having an effect on its interaction with biologically relevant structures and 
enzymes. 
 
7.1.2 Replacement of CH, CH2 and CH3 by CF, CF2 and CF3 
 
Replacement of one hydrogen atom has usually only little influence on the binding of a 
substrate by the metabolising enzyme. Many monofluoro-substituted analogues of naturally 
occurring compounds have already been tested concerning their interactions with enzymes. 
Many of them are readily accepted by enzymes in place of their non-fluorinated analogues.  
Substitution of a CH2 by a CF2 group has a larger influence on the molecule and is more likely 
to induce conformational changes (and increased conformational flexibility) in the substrate. 
This leads to lowered melting points and a widening of the angle in aliphatic chains from the 
tetrahedral angle of 109° to about 115°. 
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The trifluoromethyl group has only little in common with an ordinary methyl group. It 
resembles an isopropyl group more than a CH3 group considering the molar volume.
67 The 
van der Waals hemisphere of a CF3 group is about 2.5 times larger than that of a CH3 
group.68 Thus, replacement of three hydrogen atoms by fluorine atoms already induces large 
differences in intramolecular interactions. 
 
7.1.3 Mechanistic enzyme studies using fluorinated metabolites 
 
Mono-, di- or trifluorinated analogues of substrates for enzymes are useful tools for the 
investigation of enzymatic reaction mechanisms. Such surrogates, as for example 
fluoroacetyl-SCoA or fluoropyruvate are readily accepted by enzymes such as malate or 
citrate synthase or by L-lactate dehydrogenase, respectively.69 However, the fact that the 
fluorinated substrates are bound to the active site of an enzyme does not necessarily mean 
that they are transformed. There is nevertheless a huge difference in electronegativity 
between hydrogen and fluorine that often leads to an irreversible inhibition of an enzyme. 
Another possible outcome is that the fluoro-substituted substrate is transformed first by one 
enzyme, but the resulting product cannot be metabolised any further. This is the case for 
fluoroacetyl-SCoA in the Krebs cycle. It is readily converted to 2-fluorocitrate that inhibits 
the following enzyme of the Krebs cycle (aconitase). Therefore, fluoroacetic acid is highly 
toxic.64  
Fluorinated substrate mimetics leading to irreversible enzyme inhibition are called “suicide 
substrates” for the corresponding enzymes. They are useful tools when it comes to studying 
enzyme mechanisms. 
One possibility to use fluorinated substrate mimetics for these purposes is to observe 
whether any metabolic product accumulates in the presence of the mimetic in the medium 
of cell cultures. The cells can also be lysed to analyze the metabolic products which are not 
released into the medium. In any case, if the mimetic blocks an enzyme, the substrate for 
this enzyme will accumulate as it cannot be transformed any further. This allows isolation of 
intermediates of biosynthetic or biodegradative pathways, which are otherwise converted 
too rapidly to have any chance to analyze them. Isolation of metabolic intermediates is like 
taking snapshots of the biological pathway of interest. It makes it possible to have a closer 
look at biological transformations of which we otherwise only know the product and the 
starting material, but do not have any idea of what happens in between. This knowledge is 
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important as it provides us with means to interfere with biological pathways. Hence, it 
enables us to design active components with a high degree of specificity. 
 
7.2 Fluorinated phosphonates 
 
7.2.1 Applications 
 
Phosphonates are often used as phosphate mimetics leading to an inhibition of enzyme 
activity. This is due to the increased stability of the P-C bond towards hydrolysis compared to 
the O-P bond in phosphates.65 They are also often effective as mimetics of the tetrahedral 
intermediate of carboxylic acids during enzymatic transformations.2 This principle is used for 
mechanistic studies concerning enzymes and also for medicinal and industrial applications.64 
A special modification of this technique involves replacement of the O-P bond by a CF2-P 
bond instead of CH2-P bond. Additional fluorine atoms compensate the electronegativity loss 
due to replacing oxygen by a carbon atom. And indeed, CF2-phosphonates are very good 
phosphate mimetics in most cases.64 
 
7.2.2 Synthetic strategies to generate fluoro-substituted phosphonates 
 
The field of fluorophosphonate chemistry is still very young. The most common synthetic 
approaches towards fluorinated phosphonates can be divided into six groups: 
 direct synthesis from fluorinated-haloalkanes with phosphorous 3+ species via 
Arbuzov-type and Michaelis-Becker reactions 
 the electrophilic fluorination of phosphonate carbanions 
 nucleophilic fluorination of functionalized phosphonates (substituted with leaving 
groups of high nucleofugicity) 
 synthesis from fluorinated phosphonate carbanions 
 synthesis via addition reactions with transition metal catalysis 
 synthesis via radical reactions.65 
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7.2 Synthetic strategies towards α-hydroxy-β-aminophosphonic acids 
 
7.2.1 General strategies 
 
They interact very selectively with many biological systems and are of growing interest as 
analogues of the corresponding α-hydroxy-β-amino acids. Several synthetic strategies have 
been developed for their synthesis (Scheme 7.1). These strategies include Sharpless 
asymmetric amino-hydroxylation of unsaturated phosphonates, ammonolysis of the 
corresponding oxiranes, reduction of α-oxo-β-aminophosphonates, reaction of phosphites 
with the corresponding aldehydes or by reacting α-hydroxyphosphonates with imines. 
Enzymatic approaches are known too. α-Hydroxyphosphonates are often biologically active 
and inhibit enzymes.70 Not surprisingly, the biological effect is strongly dependent on the 
configuration at C-1. Therefore, the preparation of enantiomerically pure α-hydroxy-β-
aminophosphonates is mandatory but difficult.71  
 
 
Scheme 7.1. Approaches to α-hydroxy-β-aminophosphonates.  
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7.2.2 Enantioselective reduction of α-oxophosphonates with chiral oxazaborolidine catalysts 
 
Chiral α-hydroxyphosphonates have been generated by several methods, starting in part 
from already chiral substrates. Enzymatic resolution was another possibility to access chiral, 
nonracemic -hydroxyphosphonates described in literature.70 
The synthesis of α-hydroxyphosphonates from an achiral substrate, namely the 
corresponding α-oxophosphonates, is a totally different approach. This can be accomplished 
by reduction of -oxophosphonate with borane reagents in the presence of chiral 
oxazaborolidine catalysts (Scheme 7.2). 
 
Scheme 7.2. Reduction of α-oxophosphonates with borane and (R)-2-methyl-
oxazaborolidine as catalyst.72 
 
This method, referred to as CBS-reduction (Corey-Bakshi-Shibata), was first used for the 
reduction of 1-aryl-1-oxoalkylphosphonates in 1995.70  
 
The approach was first used in 1999 for the synthesis of entiomerically pure α-hydroxy-β-
aminophosphonates.73 The enantiomeric excess of the products obtained by this reduction 
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method resulted from the pre-coordination of the actual reductant and the ketone to the 
catalyst. Thus addition of the hydride ion can only happen from one side of the prochiral 
carbonyl group. The degree to which this reaction is enantioselective is very much 
dependent on the substrate and reflects steric effects.70 Formation of the reaction complex 
forces the delivery of the hydride ion to the carbonyl group to happen from one distinct side. 
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8. Results and discussion 
 
8.1 Aim of this Master Thesis 
 
The topic of my master thesis was the synthesis of various organic compounds, mainly 
phosphonates, in order to study the biodegradation of natural products containing a 
phosphorus-carbon bond. Compounds of this type play a crucial role in medicine (the 
antibiotic fosfomycin), agriculture (the herbicidal phosphinothricin) and other fields already 
discussed in the previous chapters. 
I focused on the synthesis of compounds useful for studying the mineralisation of fosfomycin 
and (R)-2-amino-1-hydroxyethylphosphonic acid produced by amoeba. 
3,3,3-Trifluoro-1,2-dihydroxypropylphosphonic acid (8.1), a fluorine-containing analogue of a 
postulated intermediate in the biodegradative pathway of fosfomycin, was prepared (Figure 
8.1). Its biodegradation will be evaluated later.  
 
 
Figure 8.1. Structures of target compounds. 
 
Fluorinated compounds are useful tools for unravelling metabolic processes as they can 
efficiently block certain enzymatic key steps.  
Moreover, a putative intermediate of fosfomycin biodegradation was prepared. Both 
enantiomers of 1-hydroxy-2-oxopropylphosphonic acid (6.2) were synthesised. They are 
needed to test which one is converted by a cell-extract from R. huakuii PMY1 to 
hydroxyacetone and orthophosphate. 
Furthermore, a new synthetic route to enantiomerically pure (R)-2-amino-1-hydroxy-
ethylphosphonic acid [(R)-2.1] was developed. Additionally, the synthetic route to the 
racemic compound was optimised to maximise the yield. Gram quantities of the racemate 
and the (R)-enantiomer were synthesised. These phosphonic acidswill be needed to study 
their biodegradation. 
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8.2 3,3,3-Trifluoro-1,2-dihydroxypropylphosphonic acid 
 
8.2.1 Intended use of (1R*,2R*)-3,3,3-trifluoro-1,2-dihydroxypropylphosphonic acid 
 
One target compound to be synthesised during the work for this master thesis was 
(1R*,2R*)-3,3,3-trifluoro-1,2-dihydroxypropylphosphonic acid [(1R*,2R*)-8.1]. It was 
synthesised in the racemic form containing both the (1R,2R) and the (1S,2S) enantiomer. 
This will be indicated by asterisk signs throughout the text. 
This phosphonate was prepared to study the step in the biodegradation of fosfomycin in 
which the P-C bond is cleaved. The current hypothesis concerning the biosynthetic pathway 
of this natural phosphonate is discussed in chapter 6.2. It is assumed that the fission of the 
P-C bond in the mineralisation of fosfomycin follows a mechanism similar to the one 
proposed for the biodegradation of 2-AEP. Presumably, P-C bond cleavage involves 
formation of an iminium ion between the -amino group of an active site lysine and the 
carbonyl group of 1-hydroxy-2-oxopropylphosphonic acid with possibly (R)-configuration. 
This weakens the P-C-bond so that the attack of an enzyme nucleophile or of a water 
molecule on the phosphorus atom induces P-C fission. This leads to the formation of 
phosphate and hydroxyacetone after hydrolysis of the enzyme bound intermediates 
(phosphoenzyme and enamine). However, if (1R*,2R*)-3,3,3-trifluoro-1,2-
dihydroxypropylphosphonic acid [(1R*,2R*)-8.1] is present instead of (1R,2R)-1,2-
dihydroxypropylphosphonic acid, it will probably be oxidised to the corresponding 1-
hydroxy-2-oxopropylphosphonic acid (8.2) (Scheme 8.1).  
 
 
Scheme 8.1. Possible inhibition of P-C cleavage activity. 
 
This substrate will then form imine 8.3 with the amino group of lysine. Protonation might 
not be possible because the nitrogen atom of the imine is not basic enough because of the 
strong electron withdrawing effect of the CF3 group. Consequently, no iminium cation is 
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formed and cleavage of the P-C bond is blocked. Therefore, feeding 3,3,3-trifluoro-1,2-
dihydroxypropylphosphonic acid (8.1) with the right stereochemistry, the (1R,2R)-
enantiomer, to R. huakuii PMY 1 degrading fosfomycin should lead to the accumulation of 
3,3,3-trifluoro-1-hydroxy-2-oxopropylphosphonic acid (8.2). If this could be proved, it would 
be an important indication in favour of the current hypothesis for the biodegradation of 
fosfomycin. 
 
8.2.2 Synthesis of (1R*,2R*)-3,3,3-trifluoro-1,2-dihydroxypropylphosphonic acid 
 
Former attempts by other members of the group to produce trifluoroacetaldehyde as 
starting material for this synthesis did not yield satisfying results.74 Now, the synthetic route 
for the preparation of the phosphonate uses commercially available trifluoroacetaldehyde 
hydrate (8.4) as starting material (Scheme 8.2). 
This reagent was converted to 3,3,3-trifluoropropanenitrile [(±)-8.5] by reaction with sodium 
cyanide at 0°C under highly acidic conditions. The product was extracted from the reaction 
mixture with ethyl acetate. Unfortunately, there was always quite a high amount of ethyl 
acetate present after concentration under reduced pressure. It was therefore tried to 
remove this impurity by microdistillation, which did not have the desired effect. The ethyl 
acetate to product ratio could only be reduced to about 1:1 at worst and to about 1:3 at 
best. It was feared that ethyl acetate might have an influence on the following reaction, but 
this was not the case. Therefore, the method for the preparation of the hydroxynitrile was 
not optimised and the impure product was used without any further purification. The 
product yield was calculated to be 63 mol% from the composition as determined by 1H NMR 
spectroscopy. 
 
In the next step the hydroxyl group of the 2-hydroxynitrile was protected with a 
triisopropylsilyl (TIPS) protective group using TIPS-Cl/imidazole as reagents in DMF as solvent 
(16 h at room temperature, 2 h at 50°C). The silylation should be performed as soon as 
possible as the silyl ether is more stable than the hydroxynitrile. This finding was confirmed 
by the fact that the best yield (50%) of silylated nitrile (±)-8.6 was obtained when the 
hydroxynitrile was silylated immediately after preparation. When the hydroxynitrile was 
kept at 4°C for one week in the fridge, the yield dropped to 38%.  
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Scheme 8.2. Synthetic route to compound (1R*,2R*)-8.1. 
 
The protected nitrile was reduced with DiBAl-H to give the corresponding aldehyde (±)-8.7. 
This reaction was carried out at -78°C under argon in dry toluene, the solvent of choice. The 
product was isolated by extraction with Et2O after the addition of an aqueous solution of 
NH4Cl and sulphuric acid to the reaction mixture. The desired aldehyde was obtained in 57% 
yield. The 1H NMR spectrum of the crude product showed that the major side product was a 
species derived from the TIPS protective group. It was found that the formation of the side 
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product can be reduced, if the reaction is quenched at -78°C instead of -40°C. A low 
temperature hence favoured the formation of the desired product. As the aldehyde tended 
to tail on TLC plates regardless of which eluent was used, column chromatography was not 
used to purify it.  
 
The crude aldehyde was directly converted to diethyl 3,3,3-trifluoro-1-hydroxy-2-
(triisopropylsiloxy)propylphosphonate (8.8). Therefore, diethyl trimethylsilyl phosphite was 
added to a solution of the aldehyde at -78°C. To remove the TMS protective group, a workup 
with ethanol/HCl followed. The mixture of diastereomeric hydroxyphosphonates was 
separated by flash column chromatography. All impurities could be removed. The desired 
(1R*,2R*)-diastereomer 8.8 A and the (1R*,2S*)-diastereomer 8.8 B were obtained in yields 
of 43% and 10%, respectively. The configurations were assigned analogously  to the 
unfluorinated compounds. 
 
In principle only the (1R,2R)-enantiomer is needed for the biological test. It is known from 
previous experiments with (1R*,2R*)-1,2-dihydroxypropylphosphonic acid, that only the 
(1R,2R)-enantiomer is metabolised. I suppose that in analogy to this result, the (1S,2S)-
enantiomer of the fluorinated analogue will not interfere because it is not oxidised to the 
ketone. The (1R*,2S*)-diastereomer was stored, not deprotected. However, the (1R*,2R*)-
configured substance had to be deprotected by removing the TIPS group from the oxygen 
atom and the ethyl groups from the phosphonate group to get the corresponding free 
phosphonic acid (8.1). 
The desilylation was the most difficult step of this reaction sequence. Evidently, the CF3 
group retarded the removal of the TIPS group because of its electron withdrawing effect. 
Therefore, the procedure used for the deprotection of (1R*,2R*)-diethyl 1-hydroxy-2-
(triisopropylsiloxy)propylphosphonate could not be applied to the fluorinated analogue.  
Different reaction conditions were tried to accomplish the desilylation (Table 8.1). 
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Entry Conditions Solvent Temp./°C Time/h 
Product 
Yield/mol% 
1 HF (40%) CH3CN reflux 6 4 
2 HF (40%) CH3CN 50 24 17 
3 TBAF + CH3CO2H THF -30 6 71 
4 KF + C6H5CO2H CH3CN 75 24 80 
Table 8.1. Reaction conditions for removal of TIPS. 
 
As the yield for the third and the fourth option were comparable (entries 3 and 4; 71 and 
80% respectively), the easiest procedure for deblocking of the silyl ether, method 4, was 
chosen for all following experiments. No aqueous work up was necessary. The cooled 
reaction mixture was filtered and the eluate was concentrated under reduced pressure. The 
residue could be purified easily by flash column chromatography to give a white, crystalline 
solid that was pure as judged by NMR spectroscopy and microanalysis. 
The reaction conditions for the deprotection with HF (entries 1 and 2) were too harsh. Part 
of the product was destroyed and therefore the yields were very low. Higher temperatures 
and longer reaction times did not improve the results significantly. As a better method was 
found, aqueous HF was not used as it is quite precarious to work with it. 
 
The resulting dihydroxyphosphonate (1R*,2R*)-8.9 was deprotected at phosphorus using 
bromotrimethylsilane in 1,2-dichloroethane at room temperature for two days. 
Allyltrimethylsilane was added to the reaction mixture to remove HBr which was formed by 
the reaction of the hydroxyl group with TMSBr. After concentration of the reaction mixture 
under reduced pressure, water and ethanol were added to the residue to hydrolyse the 
generated trimethylsilylated compound. This gave the free phosphonic acid (1R*,2R*)-8.1. 
No purification was necessary. The acid was converted to the corresponding ammonium salt 
by dissolving the free acid in water, adding a few drops of concentrated ammonia and 
lyophilising the resulting solution. A crystalline product which can be stored and used later 
directly was formed. The yield was assumed to be 95%, starting from TIPS-unprotected 
(1R*,2R*)-8.9. 
 
In summary, the synthesis of the ammonium salt of (1R*,2R*)-3,3,3-trifluoro-1,2-
dihydroxypropylphosphonic acid [(1R*,2R*)-8.1] could be accomplished by a sequence of six 
steps in an overall yield of 6% (see Scheme 8.2). The most critical of these steps were the 
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silylation and the formation of the P-C bond. (1R*,2S*)-diethyl 3,3,3-trifluoro-1-hydroxy-2-
(triisopropylsiloxy)propylphosphonate (8.8 B) was formed as a side product in 4 steps and 
with a poor overall yield of 2%. It was stored at this stage and may be deprotected later if 
needed.  
  
8.3 1-Hydroxy-2-oxopropylphosphonic acid 
 
8.3.1 Intended use for 1-hydroxy-2-oxopropylphosphonic acid 
 
(R)-1-Hydroxy-2-oxopropylphosphonic acid (6.2) is very likely a naturally occurring 
phosphonic acid and a putative intermediate of fosfomycin biodegradation. It has already 
been prepared as a racemate and was tested for release of orthophosphate by a culture and 
a cell-extract from R. huakuii PMY1. The racemic mixture of this compound did not support 
growth of the cell culture, but released Pi in the cell-extract. It was concluded that either its 
uptake by the microorganism did not take place or that the (S)-enantiomer inhibited 
growth.75 
Therefore, the synthesis of the two enantiomers of 1-hydroxy-2-oxopropylphosphonic acid 
was undertaken to test the metabolism of the two enantiomers separately. This could help 
to exclude the latter possibility. The (R)-enantiomer is assumed to be the natural substrate 
for the enzyme cleaving the P-C bond involved in fosfomycin biodegradation.75 
 
 
8.3.2 Synthesis of 1-hydroxy-2-oxo-propylphosphonic acid 
 
The starting material for the synthesis of 6.2 was methacrylaldehyde (8.10) which was 
reacted with dimethyl phosphite to give (±)-8.11 (Scheme 8.3). A catalytic amount of a  
 
 
Scheme 8.3. Synthesis of (±)-8.11. 
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saturated solution of sodium methoxide in methanol was needed to induce the addition of 
dimethyl phosphite to the carbonyl group. The reaction was carried out at -35°C and the 
crude product was sufficiently pure for the next reaction step. Thus, no purification was 
needed. The yield was 88%, which is very satisfying. However, if the starting aldehyde was 
not pure, the yield decreased drastically. 
Dimethyl 1-hydroxy-2-methyl-2-propenylphosphonate [(±)-8.11] was formed as a racemic 
mixture. To separate the two enantiomers, chemical resolution had to be performed. The -
hydroxyphosphonate was derivatised with Noe’s reagents (lactol and dimer of lactol). In 
principle, this reaction can give four diastereomeric acetals, but only three of these could be 
detected by 1H NMR spectroscopy (Figure 8.2). Anticipating analytical results, the two axially 
substituted acetals 8.12 A and 8.12 B derived from (R)- and (S)-hydroxyphosphonate, 
respectively, were formed preferentially because of the anomeric effect. Only one 
equatorially substituted acetal 8.13, derived from the (S)-hydroxyphosphonate was 
generated as a side product. 
 
 
   
Figure 8.2. Observed acetals derived from (±)-8.11 with Noe’s reagents. 
 
Of these three diastereomers, only the two axially substituted ones were isolated. These 
could be separated by flash column chromatography. Acetal 8.13 was the least polar of the 
three diastereomers. Therefore, flash chromatography was performed very carefully (slow 
elution of compounds) to prevent co-elution with acetal 8.12 A moving just behind 8.13. 
Afterwards the chiral auxiliary was removed again and the two enantiomers of 8.11 were 
obtained. 
Two chiral auxiliaries were tried for the derivatisation. First, the dimer [(+)-MBF-O-MBF] of 
Noe’s lactol was used (Scheme 8.4). This yielded 24% of the diastereomer containing the  
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Scheme 8.4. Preparation of (R)- and (S)-1-hydroxy-2-oxopropylphosphonic acid from 8.11. 
 
(R)--hydroxyphosphonate and 11% of the diastereomer containing the (S)--
hydroxyphosphonate. They were separated by flash chromatography as already mentioned. 
Furthermore, the formation of the acetals was also carried out with Noe’s lactol *(+)-MBF-
OH], which gave slightly higher yields of 27 and 19% for 8.12 A and 8.12 B, respectively, 
compared to the dimer of Noe´s lactol. 
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As both reactions are acid-catalysed, the addition of small amounts of para-toluenesulfonic 
acid monohydrate (p-TsOHH2O) was necessary. This method of chemical resolution had 
already been used for -hydroxyphosphonates.76 
 
Deprotection of the two acetals 8.12 A and 8.12 B gave the (R)- and (S)-enantiomer of -
hydroxyphosphonate 8.11, respectively, anticipating subsequent analytical results. p-
TsOH∙H2O was added to a solution of a diastereomerin a mixture of CH2Cl2 and methanol. 
After stirring at room temperature, the -hydroxyphosphonate was isolated and purified by 
flash chromatography. The yield for both deprotections was 78%. 
The absolute configuration of the optically active -hydroxyphosphonates was determined 
by 1H and 31P NMR spectroscopy of their (R)-Mosher esters. The phosphorus of the (R)-
Mosher ester derived from (+)-8.11, which was obtained from acetal 8.12 A, resonated at 
higher field than the phosphorus of the (R)-Mosher ester derived from (-)-8.11 (obtained 
from 8.12 B). Therefore, the dextrorotary -hydroxyphoshonate has (R)-configuration, the 
levorotary one (S), in line with previous findings. This assignment is supported by the 1H 
NMR spectra of the Mosher esters (for details see experimental part). 77,78 
 
The enantiomerically pure -hydroxyphosphonates obtained by resolution had to be 
deprotected at phosphorus to get the corresponding free phosphonic acids. As the 
enantiomerically pure starting materials for this deprotection were very precious, the 
removal of the methyl groups was optimised with the racemic compound first. This step was 
best performed by a classic method in phosphonate chemistry using bromotrimethylsilane 
(TMSBr) and allyltrimethylsilane (allylTMS). I expected no problems for this step and was 
therefore surprised by the result. 
A side reaction, probably due to the allylic character of the position next to the phosphorus 
atom, occured. A phosphonate of this type has not been deprotected by this method yet. 
NMR spectra (1H, 13C and 31P) revealed that the desired product 8.14 was accompanied by a 
high amount of an unknown impurity (product/impurity = 1:0.25). First I thought that this 
impurity could be due to the formation of HBr during demethylation, which may cause a SN2-
type exchange of the hydroxyl group by Br-. Therefore, I argued that its formation should be 
easily suppressible by first adding allyltrimethylsilane to the reaction mixture, used to trap 
HBr, and secondly bromotrimethylsilane. (As in the first experiment bromotrimethylsilane 
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was added before allyltrimethylsilane) Unfortunately, this did not affect the amount of the 
unknown impurity formed. 
A closer look at the 13C and 1H NMR shift values revealed that the signals of the impurity 
differed only slightly from those of the desired product. However, the signal for C-1 in the 
13C NMR spectrum was shifted to the lower field more than expected for a carbon atom with 
bromine instead of an oxygen atom as substituent. The finding that there were no additional 
carbon or hydrogen signals present in the unknown compound compared to the deprotected 
species led to the conclusion that the impurity was presumably dimer 8.15 (Scheme 8.5). A 
possible mechanism for its formation is given in Scheme 8.5. According to NMR 
measurements, this dimeric species was already formed before aqueous workup. 
Unfortunately, this assumption could not be verified as it was not possible to isolate 8.15 as 
tetramethyl ester after esterification of the mixture of crude acids with diazomethane. 
 
Scheme 8.5. Mechanism for formation of dimer 8.15.  
 
However, I tried to suppress its formation by lowering the reaction temperature, replacing 
1,2 dichloroethane (DCE) by CCl4 as solvent and using freshly distilled bromotrimethylsilane. 
Purification of TMSBr seemed necessary to remove traces of iron bromide formed by 
corrosion of the sure seal cap of the reagent bottle. Thus, the amount of the dimer could be 
reduced to 3 mol%. Table 8.2 gives an overview of the reaction conditions that were tried. 
  
62 
 
 
Entry 
Addition of 
reagents 
Solvent Temp./°C Reaction time/h TMSBr 
Product : 
Dimera 
1 1ST TMSBr DCE 24 6 
not 
distilled 
1 : 0.24 
2 1ST allylTMS DCE 24 3 
not 
distilled 
1 : 0.50 
3 together DCE 0 3 
not 
distilled 
1 : 0.10 
4 together DCE 0 1 
not 
distilled 
1 : 0.03 
5 together CCl4 0 3 
not 
distilled 
1 : 0.07 
6 together DCE -20 1 distilled 1 : 0.13 
7 together DCE 0 1 distilled 1 : 0.08 
Table 8.2. Conditions for deprotection of phosphonate group; a Determined by 31P NMR 
spectroscopy.  
 
Although none of the conditions given in Table 8.2 furnished only the desired product, a 
small sample of the enantiomerically pure (S)--hydroxyphosphonate 8.11 was deprotected 
at -10°C using the best conditions according to Table 8.2 (entry 4). Surprisingly, no side 
product could be detected by NMR spectroscopy. I attribute this finding to the fact that this 
substrate was homogenous as it had been purified by flash chromatography. However, the 
crude (±)--hydroxyphosphonate was regarded as “pure enough” for the next reaction step, 
but contained some minor impurities which were not identified. Possibly, these impurities 
could have an influence on the formation of dimer 8.15. The yield for the racemic sodium 
salt 8.14 was virtually quantitative, whereas deprotection of the small sample of (S)-8.11 
gave only 72% of the deprotected product. 
 
The last step in the reaction sequence leading to the sodium salt of 1-hydroxy-2-
oxopropylphosphonate was ozonolysis of the allylphosphonate 8.14 to give the 
corresponding 2-oxophosphonate 6.2. Initially, the racemic free acid was ozonolysed in a 
mixture of water and methanol at -78°C. The reaction mixture was just concentrated in 
vacuo and the residue was dissolved in water. The pH of the resulting strongly acidic solution 
was adjusted to 7 with 1 M NaOH and the solution was lyophilised afterwards. The product 
contained a large amount of formate (oxophosphonate/formate = 1 : 0.46) and phosphate 
(oxophosphonate/Pi = 1 : 0.53), as well as some minor impurities. Thus a large amount of the 
63 
 
starting material was destroyed by the ozonolysis. A shorter reaction time and a lower 
reaction temperature (-95°C) did not affect product distribution significantly. However, I 
found that ozonolysis of the sodium salt of allylphophonic acid under slightly basic 
conditions (pH = 8.0 of solution before ozonolysis), instead of  neutral ones, and the addition 
of an equimolar amount of PPh3 at -78°C after ozonolysis suppressed the formation of both 
side products efficiently. Only 2 mol% of formate were formed and no phosphate could be 
detected at all. However, the other and minor side products were still present. The aqueous 
solution of the sodium salt of (±)-6.2 was lyophilised after extractive removal of the Ph3P and 
Ph3PO. Analogously, enantiomer (S)-6.2 could be prepared with an overall yield of 9% in five 
steps.  
 
8.3.3 Stability of the sodium salts of (±) and (S)-1-hydroxy-2-oxopropylphosphonic acid 
towards racemisation in aqueous media 
 
The sodium salts of (R)- and (S)-1-hydroxy-2-oxopropylphosphonic acid will be used to study 
cleavage of their P-C bonds by cell-extracts from R. huakuii PMY1. Therefore, it is essential to 
know whether the enantiomers are labile towards racemisation in aqueous media at neutral 
pH. The mechanism for racemisation is abstraction of the proton at C-1, due to its acidity 
caused be the carbonyl and phosphonate group and reprotonation from the medium. 
 
To study racemisation, a sample of racemic oxophosphonate 6.2 was dissolved in D2O and 
the signal ratio of the hydrogen at C-1 and the hydrogens of the methyl group were 
observed as a function of time at pH 7, 8.5 and higher. If racemisation via enolate ion 
formation occurs by the proposed mechanism, H/D exchange would result. These 
experiments, which are described in more detail in chapter 9.3 in the experimental section, 
showed that the 2-oxophosphonate is sufficiently stable at pH 7 and pH 8.5 towards 
racemisation. Racemisation as determined by 1H NMR spectroscopy was fairly low (10-12%) 
within 24 hours at pH 7. However, after 5 days the α-proton had undergone a complete H/D 
exchange. 
At higher pH (> 8.5) the racemisation proceeded with a higher rate and after 6 h already 50% 
of the protons at C-1 had been exchanged for deuterium. 
 
Furthermore, the oxophosphonate to phosphate ratio was determined by 31P NMR 
spectroscopy under acidic conditions (pH ~ 4-5) as well to see whether P-C bond cleavage 
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occurs at low pH. As the phosphate/phosphonate ratio increased only insignificantly within 
24 h, the P-C bond in 2-oxophosphonate is virtually chemically stable under acidic 
conditions. Therefore, stereochemical and chemical instability will not interfere when the 
enantiomers of (R)- and (S)-1-hydroxy-2-oxopropylphosphonte will be tested as substrates 
for the enzyme splitting the P-C bond in the biodegradative pathway of fosfomycin. 
 
8.4 2-Amino-1-hydroxyethylphosphonic acid (phosphaisoserine) 
 
8.4.1 Purpose of the synthesis 
 
2-Amino-1-hydroxyethylphosphonic acid (2.1) was to be synthesised both as racemate and 
as (R)-enantiomer, which is the naturally occurring phosphonic acid analogue of isoserine.79 
These compounds are needed as substrates for the isolation of microorganisms degrading 
this natural phosphonic acid. Fairly large quantities, 20 g of the racemate and 5 g of the (R)-
enantiomer, are needed for the beginning. 
Different synthetic strategies towards 2-amino-1-hydroxyethylphosphonic acids have been 
described in chapter 7.2. Of those methods the asymmetric Sharpless amino-hydroxylation 
of vinylphosphonic acid did not seem to be attractive. Literature points out that the yields 
for a,ß-unsaturated phosphonates are significantly lower than for a,ß-unsaturated esters. 
Furthermore, only phosphonates containing an aromatic substituent in -position to the 
phosphonate group were amino-hydroxylated.80 
 
I envisaged the synthesis of racemic phosphaisoserine starting from commercially available 
vinylphosphonic acid (8.16) comprising two steps - epoxidation and ammonolysis of the 
epoxide formed (Scheme 8.6). It is known that cis-1-propenylphosphonic acid 
 
 
Scheme 8.6. Synthesis of racemic phosphaisoserine 
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can be epoxidised with hydrogen peroxide in the presence of sodium tungstate as catalyst. 
The ammonolyis of cis-1,2-epoxypropylphosphonate has been reported as well.81,82 These 
two procedures were adapted to vinylphosphonic acid. 
This approach could be used to prepare the chiral, nonracemic 2-amino-1-
hydroxyethylphosphonic acids too if chiral, nonracemic epoxides were used in place of the 
racemic epoxide. However, the enantiomeric excess of the product obtained by this method 
was limited by the enantiomeric excess of the epoxyphosphonate used as starting material 
for the ammonolysis. Unfortunately, the enantioselective epoxidation of 1-
propenylphosphonate proceeds with moderate to low ee.83 Thus, a different approach had 
to be used for the synthesis of (R)-2-amino-1-hydroxyethylphosphonic acid of high ee. 
Enantioselective reduction of an appropriate α-oxophosphonate with boranes in the 
presence of an oxazaborolidine catalyst turned out to be the method of choice. 
 
8.4.2 Optimisation of synthesis of racemic phosphaisoserine 
 
The first step of the synthesis of racemic phosphaisoserine was the epoxidation of the 
triethylammonium salt of vinylphosphonic acid (8.16). The oxidising agent was hydrogen 
peroxide. A catalytic amount of sodium tungstate, a common catalyst for the epoxidation of 
electron poor alkenes,82 and a spatula tip of EDTA were added as well. Addition of NaHCO3 
instead of tungstate which has been used for the epoxidation of unsaturated geminal di-
phosphonates did not give the desired product.84 Different reaction conditions were tested 
to maximise the conversion of the unsaturated phosphonic acid to the epoxide and to 
minimise the formation of side products.  
The major side product was found to be 1,2-dihydroxyethylphosphonic acid, the diol, by the 
addition of a small amount of authentic cyclohexylammonium salt of racemic 1,2-
dihydroxyethylphosphonic acid to the NMR sample of the reaction mixture. A set of signals 
in the 1H NMR spectrum which was already present before, increased in intensity. The same 
was true for one peak in the 31P NMR spectrum. As no new additional signals showed up, the 
side product could be identified unambiguously.  
This side product was formed by hydrolytic opening of the oxirane ring of 
epoxyethylphosphonic acid. Its formation is a function of the reaction temperature, pH and 
reaction time. If the epoxidation was carried out at higher temperatures, but for shorter 
reaction times, the formation of the side product could be suppressed considerably. After a 
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reaction time of three hours, only a small amount of the side product was visible in NMR 
spectra of the reaction mixture. Unfortunately, the conversion of vinylphosphonic acid to the 
epoxide did not exceed 50% after such a short reaction time. Therefore, the reaction time 
was increased which favoured diol formation. However, I found that the formation of 1,2-
dihydroxyethylphosphonic acid was insignificant if the reaction was performed at room 
temperature. Table 8.3 summarises the experiments which were performed to optimise this 
step. 
 
Entry Temp./°C Time/h equiv. of NEt3 Product
a 
Starting 
materiala 
Diola 
1 40 24 1.27 1 0.31 0.05 
2 60 24 1.30 1 0.38 0.14 
3 60 6 1.29 1 0.33 0.10 
4 25 72 1.30 1 0.22 0.04 
5 30 23 1.00 1 0.14 0.07 
6 30 23 0.75 1 0.29 0.53 
7 25 72 1.16 1 0.20 0.05 
Table 8.3. Reaction conditions for the epoxidation of vinylphosphonic acid; a Determined by  
1H and 31P NMR spectroscopy. 
  
The best result was achieved if the epoxidation was performed under slightly basic 
conditions with about 1.15 equivalents of NEt3 (as base) at room temperature for three days, 
although such a long reaction time is disadvantageous. Obviously, the pH was another factor 
influencing the outcome of the transformation. The fact that the crude epoxide could be 
used without prior purification for the next step was definitely an advantage. 
 
The second step was the opening of the epoxide under basic conditions with concentrated 
ammonia to give 2-amino-1-hydroxyethylphosphonic acid (±)-2.1. The temperature was 
determining the yield. If it was opened at 70°C for 24 h, the yield was about 32%. However, if 
the reaction was carried out at room temperature for three days, the yield was increased to 
40%. The range of improvement for the second step was definitely not as large as for the 
first reaction step. The longer reaction time was acceptable because of the improved yield. 
The aminophosphonic acid was isolated by ion-exchange chromatography on Dowex 50W/H+ 
using water as eluent. Fractions were collected and analysed by TLC (thin layer 
chromatography). Acids (1,2-dihydroxyethylphosphonic acid, vinylphoshonic acid and other 
acids) were not retained and were eluted first. They were followed by the 
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aminohydroxyphosphonic acid (±)-2.1. Ninhydrin-positive fractions were pooled, 
concentrated under reduced pressure and crystallised from water/ethanol. 
The epoxide opening by attack of ammonia was expected to occur for steric reasons (highly) 
regioselectively at C-2. To check whether ammonia also attacked at C-1 to give 
phosphaserine, all fractions of the ion exchange chromatography including the forerun and 
the fractions collected after elution of the desired product were analysed by TLC and by 
NMR spectroscopy. Spiking of the NMR samples with authentic phosphaserine and recording 
NMR spectra demonstrated that none contained phosphaserine. Therefore, the epoxide ring 
was opened stereospecificly. 
 
In summary, the synthesis of racemic phosphaisoerine was achieved by a two step protocol 
using vinylphosphonic acid (8.16) as starting material (Scheme 8.6). This unsaturated 
phosphonic acid was converted to the corresponding triethylammonium salt and then 
epoxidised with hydrogen peroxide in the presence of sodium tungstate. The yield for 
epoxidation was highly dependent on the temperature as well as on the pH of the reaction 
mixture. Slightly basic conditions and room temperature proved to give the best results 
concerning conversion (up to 80%). The stereospecific opening of epoxide (±)-8.17 with 
ammonia proved also to be temperature dependent and could be optimised, so that the 
isolated product yield was 50%. The overall yield for this two step sequence was 40%. 
 
8.4.3 The synthesis of (R)-2-amino-1-hydroxyethylphosphonic acid [(R)-phosphaisoserine] 
 
The synthesis of (R)-phosphaisoserine [(R)-2.1] was accomplished using a different synthetic 
route. It involved the preparation of diethyl 1-oxo-2-phthalimidoethylphosphonate (8.18) as 
key intermediate (Scheme 8.7). 
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Scheme 8.7. Envisaged route to key intermediate 8.18. 
 
This compound was chosen as it could easily be transformed into phosphaisoserine by 
reducing the carbonyl group and deblocking both the amino and phosphonic acid group. 
With this key intermediate in hands, I reasoned to have four options to obtain the chiral, 
nonracemic hydroxyphosphonate:  
 
 Enantioselective reduction of the 1-oxo group with borane dimethyl sulfide, 
BH3*(CH3)2S, and an oxazaborolidine catalyst to give the desired α-
hydroxyphosphonate. 
 Enantioselective reduction with catecholborane and an oxazaborolidine catalyst to 
give the desired enantiomer. 
 Reduction to the racemate, esterification of the -hydroxyphosphonate and enzyme-
catalysed resolution with a lipase to obtain the (R)-enantiomer. 
 Reduction to the racemate followed by derivatisation with a chiral auxiliary to give a 
pair of diastereomers which can be separated by flash chromatography and finally 
deprotected. 
 
As there was more than one way leading to the desired (R)--hydroxyphosphonate 2.1, -
oxophosphonate 8.18 met my expectations as key intermediate. Many transformations can 
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be tried with it without having to synthesise a new starting material for each one first. This 
was saving time as well as resources.  
 
The synthesis of the key intermediate was envisaged to be accomplished with glycine (8.19) 
as starting material. The amino group of this proteinogenic amino acid was protected with 
phthalic anhydride. The conversion was done solvent free by heating a well stirred mixture 
of phthalic anhydride and glycine at 160°C. Phthalimidoacetic acid (8.20) was formed and 
purified by crystallisation. Then, the acid was refluxed in thionyl chloride for 1.5 h to convert 
it to the corresponding acid chloride 8.21. The crude product could again be purified just by 
crystallisation. The overall yield for the two steps starting from cheap glycine was 82%.  
 
Next, the acid chloride was reacted with triethyl phosphite [P(OEt)3] to give oxophosphonate 
8.18. Unfortunately, this Arbuzov reaction always gave mixtures of several (seven and more) 
products. The molar ratios of the products were estimated by analysis of the 31P NMR 
spectra recorded from the reaction mixture. The reaction conditions which were tried are 
compiled in Table 8.4.  
 
Entry temp./°C time/h solvent Outcome 
1 25 2 THF 3 major and many side products 
2 25 0.5 toluene mixture of at least 8 products 
3 0 1.5 toluene 7 products 
4 0 1 CH2Cl2 at least 8 products 
5 25 1 CH2Cl2 59 mol% of the desired product 
Table 8.4. Reaction conditions for Arbuzov reaction. 
 
 The best reaction conditions gave a mixture consisting of 59 mol% of the desired -
oxophosphonate 8.18 (entry 5), but it could not be forced to crystallise. A one pot synthesis 
for these three steps was not successful either.85 
As ethyl phosphonate 8.18 could not be isolated from these reaction mixtures, I replaced 
triethyl phosphite [P(OEt)3] by triisopropyl phosphite [(P(OiPr)3] and generated diisopropyl 1-
oxo-2-phthalimidoethylphosphonate (8.22) as an alternative key intermediate (Scheme 8.8).  
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Scheme 8.8. Synthesis of (R)-2-amino-1-hydroxyethylphosphonic acid from glycine.  
 
The results for the Arbuzov reactions are summarised in Table 8.5. 
 
Entry temp./°C time/h solvent % product in reaction mixturea 
1 25 1.25 toluene 70 
2 0 1 toluene 73 
3 0 1 CH3CN 45 
4 0 1 CH2Cl2 71 
5 -20 2.25 CH2Cl2 45 
6 25 0.5 CH2Cl2 79 
Table 8.5. Reaction conditions for Arbuzov reaction between P(OiPr)3 and phthalimidoacetyl 
chloride; a determined by 31P NMR. 
 
This Arbuzov reaction appeared to be highly dependent on the temperature and the solvent 
used. In contrast to the transformation with triethyl phosphite, it produced satisfying 
amounts of the desired -oxophosphonate 8.22. However, the biggest problem after 
optimisation of the reaction conditions was the purification of the product. As the crude 
product decomposed on silica gel, flash chromatography was not appropriate for that 
purpose. Nevertheless, if the procedure was carried out quickly, a satisfactory yield of 60% 
of the desired phosphonate could be obtained.  
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By chance, I found that all impurities were readily soluble in ethyl acetate at room 
temperature, but the -oxophosphonate was only in the boiling solvent. Therefore, the -
oxophosphonate could be crystallised easily from ethyl acetate. The pale yellow crystals 
obtained were homogenous by IR, NMR spectroscopy and microanalysis. The Arbuzov 
reaction carried out in dry CH2Cl2 at room temperature for 30 minutes and followed by 
recrystallisation of the product from ethyl acetate yielded 80% of the diisopropyl -
oxophosphonate 8.22. 
 
The new key intermediate was reduced using two different agents. At first, borane dimethyl-
sulfide and (R)-2-methyl-oxazaborolidine (as catalyst) were used in different solvents and at 
different temperatures. These experiments showed that lower temperatures definitely 
produce -hydroxyphosphonates of high ee. However, it was not possible to generate α-
hydroxyphosphonates with an ee of more than 53% by reduction under these conditions. 
Interestingly, temperatures below -50°C did not bring about a higher selectivity. One 
experiment was performed using (R)-2-butyl-oxazaborolidine as catalyst to find out whether 
the longer butyl group at boron induced an additional selectivity compared to the methyl 
group. This was not the case. The results of the various reductions with borane dimethyl-
sulfide are shown in Table 8.6. 
 
Entry catalysta temp/°C time/h solvent Yield/% ee/% 
1 2-methyl 25 4.5 THF 57 30 
2 2-methyl 0 5 THF 75 34 
3 2-methyl -20 2.5 THF 86 36 
4 2-methyl -50 3 THF 68 52 
5 2-methyl -78 3 THF 62 53 
6 2-butyl -20 2.5 THF 82 22 
Table 8.6. Reduction of 8.22 with borane dimethyl-sulfide and chiral catalyst; a (R)-
oxazaborolidine. 
 
The second reducing agent tested was catecholborane showing higher selectivity than 
borane dimethyl-sulfide. And indeed, this reagent produced the desired α-hydroxy-
phosphonate (R)-8.23 with enantiomeric excesses of up to 81%. Again, these ees were 
dependent on the reaction temperature as well as on the solvent. In this case (R)-2-butyl-
oxazaborolidin did not increase the ee of the desired enantiomer as was the case for the first 
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reducing agent. Catecholborane was added to a mixture of the starting material and the 
catalyst at -78°C. Afterwards, the flask with the reaction mixture was stored at a 
temperature given in Table 8.8. The results for the reduction experiments with 
catecholborane are summarised in Table 8.8.  
 
Entry catalysta temp/°Cb time/hc solvent Yield/% ee/% 
1 2-methyl -25 5.5 toluene 75 81 
2 2-methyl -25 5.5 THF 38 23 
3 2-methyl -45 6 THF 49 25 
4 2-methyl -50 7 toluene 62 74 
5 2-butyl -25 6 toluene 65 81 
Table 8.7. Reduction of oxophosphonate 8.22 with catecholborane; a (R)-oxazaborolidine, b 
Temperature at which flask was stored after mixing reagents at -78°C, c Duration of storage. 
 
Thus, the best result for the reduction could be obtained with catecholborane as reducing 
agent and (R)-2-methyl-oxazaborolidine as catalyst at -25°C (entry 1). The yield of the (R)--
hydroxyphosphonate 8.23 was 75% and the ee 81%. The use of the 2-butyl-oxazaborolidine 
catalyst did not improve the ee and lowered the yield.  
The reduced compound could be purified easily by flash chromatography on silica gel. 
Catecholborane in general tends to tail on silica gel, but this was not the case here. The pure 
product readily crystallised. Unfortunately, it was not possible to increase its ee by 
crystallisation as the racemate seemed to crystallise first. Therefore, we wanted to try to 
increase the ee using crystallisation after the deprotection of the amino and phosphonate 
moieties. 
 
The α-hydroxyphosphonate was first deprotected by refluxing with 6 M HCl for 16 h to 
remove the isopropyl groups. The reaction mixture was concentrated under reduced 
pressure and the crude residue was stirred with concentrated ammonia at 50°C for another 
16 h. The crude (ammonium salts of the) phosphonic and phthalic acid could be purified in 
the same way as the racemate by ion exchange chromatography. Deprotection and 
purification proceeded virtually quantitatively. The enantiomeric excess of starting material 
and product was the same as determined by HPLC on chiral stationary phases (Chiracel OD-
H, hexane/isopropyl alcohol 9:1 for hydroxyphoshonate and QN-AX PF210108_1 (2009), 
methanol/TEA phosphate buffer 2 M (pH 4) 9:1 for aminophosphonic acid after 
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derivatisation with 2,4-dinitrobenzylchloroformate).86 However, it was proved to be useful 
to extract the phthalic acid with ethyl acetate prior to the purification of the phosphonic acid 
with Dowex 50W/H+. Deblocking of the amino group with hydrazine did not give satisfying 
amounts of the desired product.  
As the isolated 2-amino-1-hydroxyethylphosphonic acid is levorotary, it has (R)-configuration 
which is also the configuration of the natural product. Unfortunately, it was not possible to 
increase the ee of the purified 2-amino-1-hydroxyethylphosphonic acid by crystallisation 
from water/ethanol. The racemate seemed to crystallise first.  
 
In summary, the synthesis of (R)-2-amino-1-hydroxyethylphosphonic acid (2.1) could be 
accomplished in 6 steps starting from glycine with an overall yield of 49%. The best ee was 
81% (in favour of the desired configuration). The most critical steps were the bond formation 
between the acid chloride and the phosphite, which could be overcome by using triisopropyl 
phosphite, and the enantioselective reduction of the diisopropyl α-oxophosphonate 8.22. 
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9. Experimental Section 
 
9.1 General Remarks 
 
NMR spectra were recorded either on a Bruker DRX 600 (1H: 600.13 MHz, 13C: 150.92 MHz, 
31P: 242.94 MHz), Bruker Avance DRX 400 (1H: 400.13 MHz, 13C: 100.61 MHz, 31P: 161.98 
MHz) or a Bruker AV 400 (1H: 400.27 MHz, 13C: 100.65 MHz, 31P: 162.03 MHz) spectrometer. 
Residual solvent proton peaks (CHCl3: δH = 7.24 ppm; HOD: δH = 4.80 ppm; d6-acetone CD2H: 
δH = 2.05 ppm; d8-toluene CHD2: δH = 2.09 ppm) or CDCl3 (δC = 77.23 ppm)/ d8-toluene (δC = 
21.40 ppm) were used to reference the spectra. 
IR spectra were measured on a Bruker VERTEX 70 IR spectrometer either as films on a silicon 
disc or as ATR spectra.  
Flash (column) chromatography was carried out with Merck silica gel 60 (230-400 mesh). 
Reaction progress and flash chromatography were monitored by TLC on Merck silica gel 60 
F254 plates (0.25 mm thick). The spots were visualized by UV and/or dipping the plate into a 
molybdate solution [25 g of (NH4)6Mo7O24×4 H2O and 1 g of Ce(SO4)2×4 H2O in 500 mL of 
10% aqueous H2SO4] followed by heating with a heat gun. Compounds containing an amino 
group were made visible by dipping into a ninhydrin solution (0.2% ninhydrin in ethanol 
98%) again followed by heating the TLC plate with a heat gun.  
Melting points are generally uncorrected and were determined on a Leica Galen III Reichert 
Thermovar. 
Optical rotations were measured on a Perkin-Elmer 341 polarimeter in a 1 dm cell at 20°C. 
Enantiomeric excesses of chiral, nonracemic α-hydroxyphosphonate 8.23 and 2-amino-1-
hydroxyethylphosphonic acid (2.1) were determined via HPLC on chiral stationary phases 
(for 8.23: Chiracel-OD column, solvent: hexanes/isopropanol 9:1; for 2.1: QN-AX 
PF210108_1 (2009), solvent: methanol/TEA phosphate buffer 2M (pH 4) 9:1).87 
THF and Et2O were dried by refluxing over potassium and LiAlH4, respectively, and distillation 
before use. CCl4 and 1,2 dichloroethane were distilled from P2O5 and stored over molecular 
sieves (4 Å). All other chemicals were used as purchased from Sigma-Aldrich, Acros, Fluka or 
Merck. 
All yields are average values for optimised reaction conditions. 
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9.2 3,3,3-Trifluoro-1,2-dihydroxypropylphosphonic acid 
 
9.2.1 (±)-3,3,3-Trifluoro-2-hydroxypropanenitrile [(±)-8.5] 
 
 
Sodium cyanide (1.862 g, 38 mmol) was dissolved in water (10 mL) and the stirred solution 
was cooled to 0°C. After dropwise addition of trifluoroacetaldehyde hydrate (8.4, 3.064 g, 20 
mmol, Alfa Aesar, 75% in water) and H2SO4 (13 mL, 3 M), the solution was stirred for 24 h at 
ambient temperature. The reaction mixture was extracted with ethyl acetate (4 x 20 mL). 
The combined organic layers were dried (Na2SO4), concentrated under reduced pressure and 
dried in vacuo. The residue was purified by distillation (45 mm Hg/90-98°C) to yield 
hydroxynitrile 8.5 (2.961 g) as a colourless liquid which contained the desired product (53 
mol% as judged by 1H NMR) as well as ethyl acetate.88  The crude product was used for the 
following reaction without further purification. 
 
1H NMR (400.27 MHz, CDCl3, 4Mar2911/290 [KS1-007]): δ = 4.85 (br. s, 3H, 2 x OH and CH). 
1H NMR (400.27 MHz, D2O, 4Mar2911/350 [KS1-007 + D2O]): δ = 4.77 (q, J = 5.8 Hz, 1H, CH). 
 
9.2.2 (±)-3,3,3-Trifluoro-2-(triisopropylsiloxy)propanenitrile [(±)-8.6] 
 
 
 
3,3,3-Trifluoro-2-hydroxypropanenitrile [(±)-8.5, 1.489 g, 11.9 mmol, 53mol% 
hydroxynitrile)] was dissolved in dry DMF (12 mL) under argon at ambient temperature. 
After addition of imidazole (2.395 g, 35.5 mmol) and TIPS-Cl (3.429 g, 17.8 mmol) stirring of 
the solution was continued for 15 h at room temperature. Water (50 mL) was added after 
stirring the mixture for another two h at 50°C and the reaction mixture was extracted with 
diisopropyl ether (3 x 20 mL). The combined organic layers were washed with water (30 mL), 
dried (Na2SO4) and concentrated under reduced pressure. The residue was purified by flash 
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chromatography (hexanes/CH2Cl2 = 4:1, Rf = 0.67) to give silyl ether (±)-8.6 (1.779 g, 6.3 
mmol, 50%) as a colourless oil.89 
 
1H NMR (400.27 MHz, CDCl3, 4Mar3011/370 [KS1-008]): δ = 4.88 (q, J = 5.2 Hz, 1H, CF3CH), 
1.25-1.14 (m, 3H, 3xCHSi), 1.10, 1.08 (overlapping doublets, J = 5.7 Hz, J = 5.6 Hz, 18H, total 
of 6x CH3 of TIPS). 
13C NMR (100.65 MHz, CDCl3): δ = 121.05 (q, J = 283.3 Hz, CF3), 123.54 (s, CN), 63.08 (q, J = 
38.2 Hz, CHO), 17.47 (s, 6C, 6 x CH3 of TIPS), 11.85 (s, 3C, 3 x CHSi). 
IR (ATR): ν = 3407, 2949, 1703, 1347, 1266, 1204, 1153, 1109 cm-1. 
Anal. calcd. for C12H22F3NOSi (281.39): C 51.22%, H 7.88%, N 4.98%; found: C 51.70%, H 
7.92%,N 4.88%. 
 
 
9.2.3 (±)-3,3,3-Trifluoro-2-(triisopropylsiloxy)propane [(±)-8.7] 
 
 
 
DiBAl-H (4.92 mL, 1 M solution in hexane) was added to a stirred solution of (±)-3,3,3-
trifluoro-2-(triisopropylsiloxy)propanenitrile [(±)-8.6, 1.141 g, 4.1 mmol] in dry toluene (12 
mL) at -78°C under argon and stirring was continued for 1 h. Then Et2O (30 mL), a saturated 
aqueous solution of NH4Cl (30 mL) and H2SO4 (20 mL, 1.5 M) were added to the cooled 
solution and the resulting two-phase mixture was stirred at ambient temperature for 20 min. 
The phases were separated and the aqueous layer was extracted with Et2O (3 x 20 mL). The 
combined organic layers were washed with water (30 mL), dried (MgSO4) and concentrated 
under reduced pressure. The residue was dissolved in dry toluene (20 mL) and concentrated 
under reduced pressure to remove residual water. The oily residue was dried in vacuo to 
yield aldehyde (±)-8.7 (0.934 g, 80%) as an oil. The crude product was used without further 
purification in the following step. As it seemed not to be sufficiently stable, no column 
chromatography was performed. 
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1H NMR (400.27 MHz, CDCl3, 4Apr0611 [KS1-012]): δ = 9.55 (quin, J = 2.1 Hz, 1H, CHO), 4.36 
(qd, J = 7.0 Hz, 1.9 Hz, 1H, CF3CH), 1.15-1.05 (m, 3H, 3x CHSi), 1.04 (d, J = 4.3 Hz, 9H, 3xCH3 of 
TIPS), 1.01 (d, J = 4.3 Hz, 9H, 3xCH3 of TIPS). 
 
9.2. 4 (±)-(1R*,2R*)- and (1R*,2S*)-Diethyl 3,3,3-trifluoro-1-hydroxy-2-(triisopropylsilyloxy)-
propylphosphonate [(1R*,2R*)- and (1R*,2S*)-8.8] 
 
 
Diethyl trimethylsilyl phosphite (1.451 g, 6.9 mmol, 1.58 mL) was added dropwise to a stirred 
solution of (±)-3,3,3-trifluoro-2-(triisopropylsiloxy)propanal [(±)-8.7, 1.612 g, 5.7 mmol] 
under an argon atmosphere at -78°C in dry toluene (20 mL). The solution was allowed to 
warm up to room temperature over night, concentrated under reduced pressure and dried 
in vacuo. The residual oil was dissolved in ethanol (30 mL) and concentrated HCl (11 drops) 
was added. The solution was stirred for 2 h at ambient temperature followed by 
concentration under reduced pressure. Water (10 mL) was added andthe mixture was 
extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried (MgSO4) 
and concentrated under reduced pressure to yield a crude mixture of (1R*,2R*)-8.8 and 
(1S*,2R*)-8.8.  
The diastereomers were separated by flash chromatography (hexanes/acetone = 3:1, Rf 
(1R*,2R*- 8.8) = 0.21, Rf (1S*,2R*-8.8) = 0.13) to yield (1R*,2R*)-8.8 (0.858 g, 2.0 mmol, 35% 
from starting silylated nitrile) and (1S*,2R*)-8.8 (0.154 g, 0.4 mmol, 7% from starting nitrile). 
The products were crystallized from hexanes. 
 
(1R*,2R*)-8.8: mp 63-64°C. 
1H NMR (400.13 MHz, CDCl3, Apr1511/51 [KS1-013A]): δ = 4.58 (quint, J = 6.8 Hz, 1.1 Hz, 1H, 
CF3CH), 4.25 (m, 4H, 2 x OCH2), 4.07 (m, J = 10.6 Hz, 1H, CHP), 2.84 (d, J = 9.8 Hz, 1H, OH), 
1.33 (t, J = 7.1 Hz, 6H, 2 x CH3), 1.28 - 1.17 (m, 3H, 3 x CHSi), 1.11 (d, J = 3.5 Hz) and 1.09 (d, J 
= 3.5 Hz, total of 18H, 6 x CH3 of TIPS).  
13C NMR (100.61 MHz, CDCl3, Apr1511/50 [KS1-013A]): δ = 124.3 (qd, J = 284.9 Hz, 21.9 Hz, 
CF3), 69.6 (qd, J = 31.1 Hz, 3.2 Hz, CF3-C), 66.1 (qd, J = 169.3 Hz, 1.9 Hz, CHP), 63.6 (d, J = 7.6 
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Hz, OCH2), 62.8 (d, J = 7.6 Hz, OCH2), 18.03 (s, 3C, 3 x CH3 of TIPS), 18.01 (s, 3C, 3 x CH3 of 
TIPS), 16.7 (d, J = 5.7 Hz, CH3), 16.7 (d, J = 6.0 Hz, CH3), 13.0 (s, 3C, CHSi). 
31P NMR (162.03 MHz, CDCl3, 4Apr0811/511): δ = 19.6 (q, J = 3.9 Hz). 
IR (Si, [KS1-013A]):  = 3268, 2945, 2869, 1462, 1264, 1164, 1139, 1025, 971 cm -1. 
Anal. calcd. for C16H34F3O5Psi (422.51): C 45.49%, H 8.11%; found: C 45.53%, H 8.05%.  
 
(1S*,2R*)-8.8: mp 51-52°C. 
1H NMR (400.13 MHz, CDCl3, Apr1511/41 [KS1-013B]): δ = 4.56 - 4.46 (m, 1H, CF3CH), 4.25-
4.11 (m, 5H, 2 x OCH2 and CHP), 2.90 (br s, 1H, OH), 1.33 (td, J = 7.0 Hz, 0.3 Hz, 6H, 2 x CH3), 
1.20 - 1.03 (m, 21H, 3 x TIPS). 
13C NMR (100.61 MHz, CDCl3, Apr1511/40 [KS1-013B]): δ = 124.1 (qd, J = 284.1 Hz, 3.4 Hz, 
CF3), 72.2 (qd, J = 30.9 Hz, 6.3 Hz, CF3C), 70.5 (d, J = 161.2 Hz, CHP), 63.4 (d, J = 5.8 Hz, OCH2), 
63.3 (d, J = 6.9 Hz, OCH2), 18.1 (s, 3C, 3 x CH3 of TIPS), 18.0 (s, 3C, 3 x CH3 of TIPS), 16.6 (d, J =  
9.0 Hz, 2C, 2 x CH3), 12.7 (s, 3C, 3 x CHSi). 
31P NMR (162.03 MHz, CDCl3, Apr1511/42 [KS1-013B]): δ = 18.5 (s).  
IR (Si):  = 3266, 2946, 2870, 1467, 1262, 1177, 1140, 1054, 1026 cm-1.  
Anal. calcd. for C16H34F3O5PSi (422.51): C 45.49%, H 8.11%, O 18.93%; found: C 45.70%, H 
7.97%,  O 18.78% 
 
9.2.5 (1R*,2R*)-Diethyl 3,3,3-trifluoro-1,2-dihydroxypropylphosphonate [(1R*,2R*)-8.9] 
(Method A)  
 
 
The silylated phosphonate [(1R*,2R*)-8.8, 0.775 g, 1.8 mmol] was dissolved in dry 
acetonitrile (40 mL) together with sodium fluoride (0.521 g, 9.0 mmol) and benzoic acid 
(1.098 g, 9.0 mmol). The resulting mixture was stirred for 16 h at 70°C under argon 
atmosphere. The cooled solution was concentrated under reduced pressure and the crude 
product was purified by flash chromatography (ethyl acetate, Rf = 0.45) to yield diol 
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(1R*,2R*)-8.9 (0.477 g, 1.7 mmol, 94%). The product was crystallised from hexanes/CH2Cl2 to 
give colourless needles;90 mp 38-40°C.  
 
1H NMR (400.13 MHz, CDCl3, Mar2111/20 [KS1-005]): δ = 5.40 (br. s, 1H, OH), 4.75 (br. s, 1H, 
OH), 4.32-4.14 (m, 6H, 2 x OCH2, CF3CH and CHP), 1.34 (t, J = 7.1 Hz, 6H, 2 x CH3). 
13C NMR (100.61 MHz, CDCl3, Mar2111/22 [KS1-005]): δ = 124.4 (qd, J = 283.7 Hz, 22.8Hz, 
CF3), 69.3 (qd, J = 31.2 Hz, 3.1 Hz, CF3-C), 66.8 (qd, J = 166.7 Hz, 1.1 Hz, CH-P), 64.3 (d, J = 7.0 
Hz, OCH2), 63.9 (d, J = 7.4 Hz, OCH2), 16.6 (d, J = 5.3 Hz, CH3), 16.5 (d, J = 5.3 Hz, CH3). 
31P NMR (161.98 MHz, CDCl3, Mar2111/21 [KS1-005]): δ = 21.8 (q, J = 4.4 Hz). 
IR (Si, [KS1-005]):  = 3255, 2985, 1276, 1260, 1166, 1137, 1029 cm-1. 
Anal. calcd. for C7H14O5F3P (265.19): C 31.59%, H 5.30%, O 30.06%; found: C 31.43%,  H 
5.18%,  O 29.84% 
 
9.2.6 (1R*,2R*)-Diethyl 3,3,3-trifluoro-1,2-dihydroxypropylphosphonate [(1R*,2R*)-8.9] 
(Method B)  
 
 
Tetra-n-butylammonium fluoride (0.5 mL, 1M solution in THF) and acetic acid (0.03 mL, 98%) 
were added to a stirred solution of (1R*,2R*)-8.8 (0.100 g, 0.24 mmol) in dry THF (3 mL) at     
-30°C. Stirring was continued for 6 h and then the solution was allowed to warm up to 
ambient temperature in the cooling bath. The reaction mixture was diluted with ethyl 
acetate (10 mL) and a saturated aqueous solution of NaHCO3 (6 mL). The layers were 
separated, the organic phase was extracted with a saturated aqueous solution of NaHCO3 
(10 mL) and brine (10 mL), dried (MgSO4) and concentrated under reduced pressure. The 
crude product was purified by flash chromatography (ethyl acetate/hexanes = 3:1, Rf = 0.38) 
to yield dihydroxyphosphonate (1R*,2R*)-8.9 (0.045 g, 0.17 mmol, 71%)91. 
 
The spectra were identical to those reported for the compound prepared by Method A. 
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9.2.7 Ammonium salt of (1R*, 2R*)-3,3,3-trifluoro-1,2-dihydroxypropylphosphonic acid 
[(1R*,2R*)-8.1] 
 
 
A mixture of dihydroxyphosphonate (1R*,2R*)-8.9 (0.330 g, 1.2 mmol), 
bromotrimethylsilane (1.470 g, 9.6 mmol, 1.27 mL) and allyltrimethylsilane (0.069 g, 0.6 
mmol, 0.10 mL) in 1,2-dichloroethane (7.5 mL) was stirred for 3 d at ambient temperature. 
Afterwards the volatile components were removed under reduced pressure (0.5 mm 
Hg/room temperature, then 35°C). The residual liquid was dissolved in water/ethanol (10 
mL, 1:1) and stirred for 3 h at room temperature. The solution was concentrated again to 
give a white powdery solid. Water (3 mL) and a concentrated ammonia solution (5 drops, 
25%) were added. The solution was lyophilised to give the ammonium salt of (1R*,2R*)-8.1 
(0.219g, 99%); mp 172-175°C. 
 
1H NMR (400.13 MHz, D2O, Mar3011/60 [KS1-006]): δ = 4.42 (qdd, J = 7.6 Hz, J = 4.8 Hz, J = 
0.9 Hz, 1H, CF3CH), 3.99 (dd, J = 13.0 Hz, 0.8 Hz, 1H, CHP). 
13C NMR (100.61 MHz, D2O, Mar3011/61 [KS1-006]): δ = 125.3 (qd, J = 282.2 Hz, 19.1 Hz, 
CF3C), 69.7 (qd, J = 30.3 Hz, 1.8 Hz, CF3), 66.6 (d, J = 147.6 Hz, CHP). 
31P NMR (161.98 MHz, D2O, Mar3011/62 [KS1-006]): δ = 15.7 (s). 
IR (ATR, [KS1-016]):  = 3019, 2816, 1437, 1264, 1114, 1038, 970 cm-1. 
 
9.3 (±)-1-Hydroxy-2-oxopropylphosphonic acid 
 
9.3.1 (±)-Dimethyl 1-hydroxy-2-propenylphosphonate [(±)-8.11] 
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A saturated solution (0.1 mL) of NaOMe in methanol was added to a stirred mixture of 
methacroleine (8.10, 0.701 g, 10.0 mmol, 0.83 mL) and dimethyl phosphite (0.781 g, 10.0 
mmol, 0.65 mL) in Et2O (20 mL) under an argon atmosphere at -35°C. After stirring for 30 
min at -35°C concentrated H2SO4 (9 drops) was added. The reaction mixture was allowed to 
warm to room temperature and the solvent was removed under reduced pressure. The 
crude product was dissolved in toluene/CH2Cl2 (10 mL, 1:1) filtered and dried in vacuo to 
yield hydroxyallylphosphonate (±)-8.11 (1.579 g, 8.8 mmol, 88%) as colourless oil.92 The 
product was used for the following reaction without further purification. For future 
experiments it might be useful to add H2SO4 in a quantity sufficient to neutralise the base 
and purify the crude -hydroxyphosphonate by flash chromatography. 
 
The recorded spectra are identical to those reported in the literature.92 
1H NMR (400.13 MHz, CDCl3): δ = 5.17 (dq, J = 4.9 Hz, 1.0 Hz, 1H, CH=), 5.05 (dq, J = 2.5 Hz, 
1.0 Hz, 1H, CH=), 4.43 (dd, J = 12.8 Hz, 5.9 Hz, 1H, CHP), 4.01 (dd, J = 9.4 Hz, 5.9 Hz, 1H, OH), 
3.788 and 3.785 (2 d, J = 10.8 Hz, 2 x 3H, 2 x OCH3), 1.87 (dt, J = 3.8 Hz, 3H, CH3). 
13C NMR (100.61 MHz, CDCl3): δ = 140.8 (d, J = 3.8 Hz, Cq), 113.9 (d, J = 11.1 Hz, CH2), 71.8 (d, 
J = 157.1 Hz, CH-P), 53.7 (d, J = 6.9 Hz, OCH3), 53.6 (d, J = 7.1 Hz, OCH3), 19.5 (d, J = 2.2 Hz, 
CH3).  
31P NMR (161.98, CDCl3, Jul2611/10 [KS2-008]): δ = 24.0 (s, integration: 1.00), 27.5 (s, 
integration: 0.07). 
IR (ATR, [KS2-008]):  = 3260, 2960, 1460, 1223, 1184, 1058, 1023, 905 cm-1. 
 
9.3.2 Acetals of (±)-dimethyl 1-hydroxy-2-methylallylphosphonate (8.12 A and 8.12 B) derived 
from Noe´s lactol and its dimer 
 
 
After stirring the crude α-hydroxyphosphonate [(±)-8.11, 2.748 g, 15 mmol] over molecular 
sieves (4Å) in dry CH2Cl2 (60 mL) for 15 min, the solution was cooled to 0°C. (+)-Noe´s lactol 
[(+)-MBF-OH, 2.944g, 15 mmol], p-toluenesulfonic acid monohydrate (0.094 g, 0.6 mmol) 
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were added and stirring was continued for 1 h. The molecular sieves were removed by 
filtration, the reaction mixture was extracted with a saturated aqueous solution of NaHCO3 
(3 x 20 mL), the organic layer was separated and dried (MgSO4). The solution was 
concentrated under reduced pressure. The crude mixture was separated by flash 
chromatography [gradient: ethyl acetate/PE (1:1)  ethyl acetate, Rf (A) = 0.36 and Rf (B) = 
0.29 in ethyl acetate] to yield diastereomers 8.12 A (1.452 g, 4.1 mmol, 27 %) and 8.12 B 
(1.005 g, 2.8 mmol, 19%) as oils.76 
 
The acetalisation with (+)-MBF-O-MBF was performed similarly, except that only 0.5 
equivalents relative to hydroxyphosphonate were used. 
 
Diastereomer (1R*,2R*)-8.12: 1H NMR (400.27 MHz, d8-toluene, 4Jun0711/460 [KS2-006A]): 
δ = 5.17 (br d, J = 4.7 Hz, 1H, OCHO), 5.15 - 5.10 (m, 1H, CH=), 5.02 (sept, J = 1.6 Hz, 1C, CH=), 
4.68 (d, J = 18.7 Hz, 1H CHO), 4.43 (dd, J = 9.5 Hz, 1.6 Hz, 1H, CHP), 3.53 (d, J = 10.4 Hz, 3H, 
OCH3), 3.48 (d, J = 10.5 Hz, 3H, OCH3), 2.88 - 2.77 (m, 1H, CH), 1.96 - 1.93 (m, 3H, CH3C=), 
1.90 - 1.82 (m, 1H, CH), 1.76 - 1.61 (m, 2H, 2 x CH), 1.50 - 1.35 (m, 2H, 2 x CH), 1.27 (ddd, J = 
13.5 Hz, 9.1 Hz, 4.2 Hz, 1H, CH), 1.11 (tdd, J = 12.2 Hz, 3.8 Hz, 1.5 Hz, 1H, CH), 0.90 (s, 3H, 
CH3), 0.89 (s, 3H, CH3), 0.81 (s, 3H, CH3). 
13C NMR (100.61 MHz, d8-toluene): δ = 140.9 (s, 1C, Cq), 117.0 (d, J = 12.2 Hz, CH2=), 106.8 (d, 
J = 12.2 Hz, OCHO), 90.9 (s, CHO), 75.5 (d, J = 169.0 Hz, CHP), 54.1 (d, J = 6.1 Hz, POCH3), 53.8 
(s, Cq), 53.4 (d, J = 6.1 Hz, POCH3), 49.8 (s, Cq), 48.7 (s, CH), 41.5 (s, CH), 33.4 (s, CH2), 27.8 (s, 
CH2), 21.9 (s, CH3), 21.6 (s, CH2), 20.6 (s, CH3), 19.7 (s, CH3), 16.0 (s, CH3). 
31P NMR (162.03 MHz, d8-toluene, 4Jun0711/461 [KS2-006A]): δ = 22.1 (s). 
IR (Si):  = 2954, 1451, 1262, 1181, 1040 cm-1. 
 
Diastereomer (1R*,2S*)-8.12: 1H NMR (400.27 MHz, d8-toluene, 4May3111/30 [KS2-002B]): 
δ = 5.64 (d, J = 4.7 Hz, 1H, OCHO), 5.23 - 5.18 (m, 1H, CH=), 4.97 - 4.87 (m, 1H CH=), 4.49 (d, J 
= 13.3 Hz, 1H, CHO), 4.25 (dd, J = 9.5 Hz, 1.4 Hz, 1H, CH-P), 3.50 (d, J = 10.6 Hz, 3H, OCH3), 
3.47 (d, J = 10.6 Hz, 3H, OCH3), 2.86 - 2.76 (m, 1H, CH), 1.97 - 1.92 (m, 3H, CH3C=), 1.90 - 1.67 
(m, 3H, CH3), 1.47 - 1.33 (m, 2H, 2 x CH), 1.32 - 1.23 (m, 1H, CH), 1.15 - 1.05 (m, 1H, CH), 0.85 
(s, 3H, CH3), 0.83 (s, 3H, CH3), 0.78 (s, 3H, CH3). 
13C NMR (100.61 MHz, d8-toluene): δ = 142.6 (s, =Cq), 114.6 (d, J = 10.7 Hz, CH2), 110.3 (d, J = 
5.4 Hz, OCHO), 91.3 (s, CHO), 76.7 (d, J = 161.4 Hz, CHP), 53.721 (d, J = 6.9 Hz, 2C, 2 x OCH3), 
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53.720 (s, Cq), 53.71 (d, J = 6.9 Hz, OCH3), 49.77 (s, Cq), 48.75 (s, CH), 41.5 (s, CH), 33.81 (s, 
CH2), 27.8 (s, CH2), 21.9 (s, CH3), 21.8 (s, CH2), 21.0 (s, CH3), 19.7 (s, CH3), 15.8 (CH3). 
31P NMR (162.32 MHz, d8-toluene, 4May3111/31 [KS2-002B]): δ = 22.6 (s, integration: 1.00, 
desired product), 25.9 (s, integration: 0.06), 25.9 (s, integration: 0.04). 
IR (Si):  = 2954, 1458, 1259, 1182, 1099, 1033, 985 cm-1. 
 
9.3.3 (R)- and (S)-Dimethyl 1-hydroxy-2-methylpropylphosphonate [(R)- and (S)-8.11] 
 
Deprotection of diastereomer 8.12 A: 
 
 
p-Toluenesulfonic acid monohydrate (0.062 g, 0.4 mmol) was added to a stirred solution of 
diastereomer 8.12 A (1.452 g, 4.1 mmol) in dry CH2Cl2 (30 mL) and dry methanol (9 mL) at 
room temperature. The resulting solution was stirred for 2.5 h before addition of a small 
amount of solid NaHCO3. Stirring was continued for 10 min, the reaction mixture was filtered 
and concentrated under reduced pressure. The residue was purified by flash 
chromatography (ethyl acetate, Rf = 0.23) to give (R)-8.11 (0.598 g, 3.3 mmol, 80%) as a 
colourless oil. The product was crystallized from diisopropyl ether to give colourless crystals; 
[]D
20 = +2.81 (c 0.93, acetone). 
 
The NMR data are identical to those of the racemic compound. 
 
Deprotection of diastereomer 8.12 B: 
 
Similarly, diastereomer 8.12 B (1.005 g, 2.8 mmol) was deprotected to give -
hydroxyphosphonate (S)-8.11 (0.424 g, 2.4 mmol, 86%). The product was crystallized from 
diisopropyl ether; []D
20 = -2.80 (c 0.97, acetone), mp 47-49°C. 
 
The NMR data are identical to those of the racemic compound. 
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9.3.4 Sodium salt of (±)- and (S)-1-hydroxy-2-methylpropylphosphonic acid [(±)- and (S)-8.14] 
 
 
 
Removal of methyl groups from racemic 8.11: 
 
Dimethyl phosphonate (±)-8.11 (0.410 g, 2.3 mmol) was dissolved in 1,2-dichloroethane (2.3 
mL) under an argon atmosphere at 0°C. Allyltrimethylsilane (0.503 g, 4.4 mmol, 0.7 mL) and 
bromotrimethylsilane (1.183 g, 7.7 mmol, 1.02 mL) were added simultaneously to the stirred 
solution and stirring was maintained for 1 h at 0°C. All volatile components were removed 
under reduced pressure (1 mbar) at room temperature and the residue was dissolved in H2O 
(10 mL). After adjusting the pH to 7 with 1 M NaOH, the aqueous solution was lyophilised to 
yield a sodium salt of (±)-8.14 as a white solid (0.451 g, 2.3 mmol, 99%).93 
 
1H NMR (400.27 MHz, D2O, 4Jul1311/70 [KS2-013 Lyo]): δ = 5.08 (d, J = 2.0 Hz, 1H, CH=), 5.01 
(s, 1H, CH=), 4.24 (d, J = 13.6 Hz, 1H, CHP), 1.90 (s, 3H, CH3). 
13C NMR (100.61 MHz, D2O, 4Jun2411/70 [KS2-013]): δ = 144.4 (d, J = 3.2 Hz, Cq), 112.6 (d, J = 
9.8 Hz, CH2=), 74.4 (d, J = 150.0 Hz, CHP), 19.7 (d, J = 1.5 Hz, CH3). 
31P NMR (162.03 MHz, D2O, 4Jul1311/71 [KS2-013]): δ = 15.9 (s, integration: 1.00, desired 
product), 11.5 (s, integration: 0.03, unknown impurity), 19.6 (s, integration: 0.05, unknown 
impurity). 
IR (ATR, [KS2-009]):  = 3216, 1645, 1449, 1376, 1154, 1061,892 cm-1. 
 
It was assumed that the impurity with signal integration 0.03 in the 31P NMR spectrum was 
caused by the dimeric species (see chapter 8.3.2). 
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Removal of methyl groups from -hydroxyphosphonate (S)-8.11: 
 
Similarly, the corresponding sodium salt of (S)-phosphonic acid (S)-8.14 (0.184 g, 0.9 mmol, 
72%) was obtained from phosphonate (S)-8.11 (0.235 g, 1.3 mmol), []D
20 = +3.8 (c 0.99, 
water). 
 
1H NMR (400.27 MHz, D2O, 4Jul2011/30 [KS2-019]): δ = 5.10 (br. d, J = 2.9 Hz, 1H, CH=), 5.00 
(br. s, 1H, CH=), 4.28 (d, J = 13.9 Hz, 1H, CH-P), 1.90 (s, 3H, CH3). 
13C NMR (100.65 MHz, D2O, 4Jul2611/42 [KS2-019]): δ = 143.8 (d, J = 3.5 Hz, Cq), 112.3 (d, J = 
9.5 Hz, CH2), 73.9 (d, J = 149.5 Hz, CHP), 19.2 (d, J = 1.5 Hz, CH3). 
31P NMR (162.02 MHz, D2O, 4Jul2011/31 [KS2-019]): δ = 16.4 (s). 
IR (ATR, [KS2-019]):  = 3226, 2832, 2729, 2324, 1648, 1128, 1075, 1021, 986, 892 cm-1. 
 
The impurities which were present in the sodium salt of racemic phosphonate 8.14 could not 
be detected for the sodium salt of the (S)-enantiomer. Therefore, I concluded that those 
impurities were derived from the impurity in the starting -hydroxyphosphonate, which was 
not present in the enantiomerically pure starting material as it was purified by column 
chromatography prior to use contrary to the racemate. 
 
Preparation of (R)-Mosher esters exemplified for Mosher esters of (+)-hydroxyphosphonate 
8.11: 
 
A solution of (+)-hydroxyphosphonate 8.11 (0.0216 g, 0.12 mmol, derived from diastereomer 
8.12 A, dried by coevaporation with toluene), dry pyridine (1 mL), dry CH2Cl2 (0.5 mL) and 
(S)-MTPACl (0.4 mL, 0.5 M solution in dry CH2Cl2, 0.2 mmol) was left at room temperature 
for 18 h. No spot of remaining hydroxyphosphonate was visible on TLC (hexanes/ethyl 
acetate = 1:1). Water (5 mL) and HCl (5 mL, 2 M) were added and the mixture was stirred for 
10 min. It was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were washed 
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with a saturated aqueous solution of NaHCO3 and water, dried (Na2SO4) and concentrated 
under reduced pressure. The residue was purified by flash chromatography (hexanes/ethyl 
acetate = 1:1, Rf = 0.60) to give the (R)-Mosher ester (0.037 g, 78%) as an oil.
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1H NMR (400.13 MHz, CDCl3), significant signals: δ = 3.57 (q, J = 1.0 Hz, 3H, OCH3), 1.81 (br. s, 
3H, CH3C=). 
31P NMR (161.98 MHz, CDCl3): δ = 19.73 (s). 
 
Similarly, -hydroxyphosphonate (-)-8.11 derived from diastereomer 8.12 B was derivatised 
to give (R)-Mosher ester (0.031 g, 65%) as an oil. 
 
1H NMR (400.13 MHz, CDCl3), significant signals: δ = 3.54 (q, J = 1.0 Hz, 3H, OCH3), 1.91 (br. s, 
3H, CH3C=). 
31P NMR (161.98 MHz, CDCl3): δ = 19.27 (s). 
 
9.3.5 Sodium salt of (±)- and (S)-1-hydroxy-2-oxopropylphosphonic acid [(S)-6.2]  
 
 
 
Ozonolysis of sodium salt of (±)-8.14: 
 
The sodium salt of α-hydroxyallylphosphonic acid (±)-8.14 (0.349 g, 1.7 mmol) was dissolved 
in H2O (1.7 mL) and the solution was diluted with methanol (17 mL). Ozone was bubbled 
through the stirred solution at -78°C for 4 min until the reaction mixture turned cobalt blue. 
Afterwards air was bubbled through the solution to remove excess ozone. PPh3 (0.445 g, 1.7 
mmol) dissolved in CH2Cl2 (2 mL), was added and stirring was continued at -78°C for 10 min. 
The mixture was allowed to warm up to room temperature. This was followed by removing 
the solvent under reduced pressure. The residue was dissolved in water (15 mL), CH2Cl2 (15 
mL) was added, the phases were separated and the aqueous layer was extracted with CH2Cl2 
87 
 
(3 x 15 mL). Residual organic solvents were removed from the aqueous phase under reduced 
pressure and its pH was adjusted to pH 7 with NaOH (1M). Finally, the resulting solution was 
lyophilised to yield a sodium salt of 1-hydroxy-2-oxopropylphosphonate [(±)-6.2, 0.355 g, 1.7 
mmol, 99%] as white, powdery solid.93 
 
1H NMR (400.27 MHz, D2O, 4Jul2911/250 [KS2-023 0h]): δ = 4.64 (d, J = 18.7 Hz, 1H, CHP), 
2.38 (s, 3H, CH3). 
13C NMR (100.65, D2O, 4Jul2911/252 [KS2-023 0h]): δ = 212.3 (d, J = 7.0 Hz, C=O), 80.0 (d, J = 
120.4 Hz, CHP), 27.1 (s, CH3). 
31P NMR (162.03 MHz, D2O, 4Jul2911/251 [KS2-023 0h]): δ = 19.17 (s, integration: 0.06), 
13.02 (s, integration: 0.01), 9.14 (s, integration: 1.00, desired product), 5.43 (s, integration: 
0.11), 4.63 (s, integration: 0.04), 2.20 (s, integration: 0.05, phosphate). 
IR (ATR, [KS2-023]):  = 3179, 1689, 1417, 1358, 1076, 964 cm-1. 
 
Stability of racemic 1-hydroxy-2-oxo-propylphosphonic acid towards racemisation at pH 7: 
 
A sample of compound (±)-6.2 was analysed by NMR spectroscopy. Racemisation occurring 
due to the acidity of the proton in α-position to both the oxo- and the phosphonic acid group 
was investigated. Therefore, it was dissolved in D2O and the ratio of the methyl group (δ = 
3.07 ppm, which was not supposed to undergo H/D exchange) and the signal assigned to the 
CHP group (δ = 4.63 ppm, d, J = 18.7 Hz, 1H) was measured as a function of time. (The 
methyl group protons are supposed not to undergo H/D exchange, but the CHP proton is 
likely to exchange.)  If H/D-exchange occurred, the ratio of the 1H NMR resonances of CH3 to 
CHP should increase with time (Table 9.1).  
 
 
Table 9.1. Stability of (±)-6.2 towards racemisation at pH 7. 
 
Entry Reaction time integration of CH3 integration of CHP 
1 0 h 3 0.97 
2 6 h 3 0.96 
3 24 h 3 0.88 
4 5 days 3 0.00 
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This clearly shows that racemisation due to the acidity of the hydrogen atom of the CHP 
group is a very slow process (about 10% in 24 h). However, after 5 days H/D exchange was 
nearly complete. 
 
Stability of racemic 1-hydroxy-2-oxo-propylphosphonic acid towards racemisation under 
basic conditions: 
 
The pH of a small sample of sodium salt of 6.2 was adjusted to pH 8.5 with 1M NaOH in H2O. 
Water was removed and the sample was dissolved in D2O. The integration ratio between the 
formate proton (formate forms during the reaction and is therefore present in the resulting 
reaction mixture) and the CHP proton was observed as a function of time. The principle is 
the same as already explained for pH 7, but this time the formate proton integral was used 
as a reference value instead of the methyl group integral. It is not likely to undergo H/D-
exchange either (Table 9.2). 
 
Entry 
Time after 
adjustment of pH 
Integration of formate proton 
Integration of CHP 
proton 
1 0 h 1.00 2.00 
2 2 h 1.00 1.88 
3 5 h 1.00 1.76 
Table 9.2. Stability of (±)-6.2 towards racemisation  at pH 8.5. 
 
These measurements show that the compound is sufficiently stable over the intended 
testing period in a solution of slightly basic pH. 
 
Afterwards one drop of 1M NaOD in D2O was added to the sample and the same ratio was 
analysed. 
 
With this measurement it was possible to show that racemisation does occur at pH higher 
than 8.5 within a shorter period (Table 9.3).  
 
Entry Time after addition 
of NaOD 
Integration of formate 
proton 
Integration of CHP 
proton 
1 0 h 1.00 2.00 
2 16 h 1.00 0.82 
  Table 9.3. Stability of (±)-6.2 towards racemisation  at pH > 8.5. 
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However, the rate of H/D exchange proved to be much slower than originally expected. 
 
Stability of racemic 1-hydroxy-2-oxopropylphosphonic acid towards cleavage of the P-C bond 
under acidic conditions: 
 
One drop of DCl in D2O was added to an NMR sample of 6.2 in D2O and the ratio of 
phosphate, which was present from the beginning (δ = 1.58 ppm), to product was observed 
by 31P NMR spectroscopy. As the data shows, P-C bond cleavage is negligible (5% at most in 
25h): 
 
Entry 
Time after addition 
of DCl 
Integration of phosphate 
signal 
Integration of 
product signal 
1 before addition 0.61 1 
2 0 h 0.59 1 
3 2 h 0.61 1 
4 5 h 0.62 1 
5 25 h 0.67 1 
Table 8.4. Chemical stability of (±)-6.2 
 
Ozonolysis of (S)-8.14: 
 
Similarly, the sodium salt of (S)-1-hydroxy-2-methyl-2-propenylphosphonic acid was 
ozonolysed and gave the sodium salt of (S)-6.2 (140 mg, 0.7 mmol, 99%) as white powdery 
solid. 
 
1H NMR (400.27 MHz, D2O, 4Aug3111/130 [KS2-025]): δ = 4.65 (d, J = 19.0 Hz, 1H, CHP), 2.38 
(s, 3H, CH3). 
31P NMR (162.03 MHz, D2O), 4Aug3111/131 [KS2-025]: δ = 9.4 (s, 1.00, desired product), 3.7 
(s, 0.02, unknown byproduct), 1.17 (s, 0.05, phosphate). 
IR (ATR, [KS2-023]):  = 3171, 1690, 1357, 1070, 964 cm-1. 
*α+D
20 = +94.8 (c 1.01), when left for 5 h at room temperature: *α+D
20 = +93.2 (c 1.01), for 24 
h: *α+D
20 = +85.2 (c 1.01). 
  
9.4 2-Amino-1-hydroxyethylphosphonic acid 
 
9.4.1 (±)-Oxiran-2-yl-phosphonic acid [(±)-8.17] 
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Vinylphosphonic acid (8.16, 3.995 g, 37 mmol, 90% in water) was dissolved in isopropyl 
alcohol (18 mL), NEt3 (4.380 g, 43 mmol, 6 mL) was added to the solution at room 
temperature. K3EDTA × 2 H2O (0.075 g, 0.2 mmol) , Na2WO4 × 2 H2O (0.627 g, 1.9 mmol) and 
H2O2 (9.5 mL, 30%) were added to the stirred solution. After 4 h a second portion of H2O2 
(9.5 mL, 30%) was added and the mixture was kept at ambient temperature for 3 d. 
1H and 31P NMR revealed the degree of conversion of vinylphosphonic acid to the 
corresponding epoxide (±)-8.17 to be 80 mol%. The formation of 1,2-
dihydroxyethylphosphonic acid, which was the major side product if the reaction was carried 
out at higher temperatures could be reduced to 4 mol% when the epoxidation was 
performed at room temperature for 3 d. 
A spatula tip of MnO2 was added to destroy excess H2O2. The mixture was filtered (celite 
moistened with ethanol) and concentrated under reduced pressure. The crude epoxide (±)-
8.17 was used without further purification for the following step.82 
 
1H NMR of the reaction mixture before workup (400.27 MHz, D2O + NaOD, 4Mar1411/60 
[KS3-001 roh 4]): δ(vinylphosphonic acid) = 6.28 - 6.12 (m, 1H, CHP), 6.03 - 5.78 (m, 2H, CH2). 
δ(epoxide) = 3.51 (q, J = 7.0 Hz, 1H, CHP), 3.08 - 3.02 (m, 1H, CH2), 3.00-2.91 (m, 1H, CH2). 
31P NMR of the reaction mixture before workup (162.03 MHz, D2O + NaOD): 14.5 (s, caused 
by diol, 4%), 11.0 (s, epoxide, 80%), 10.6 (s, vinylphosphonic acid, 16%). 
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9.4.2 (±)-Phosphaisoserine [(±)-2.1] 
 
 
The crude triethylammonium salt of the epoxyphosphonic acid (±)-8.17 (30 mmol) was 
dissolved in an aqueous ammonia solution (50 mL, 25%) and stirred for 3 d at room 
temperature. The reaction mixture was then concentrated under reduced pressure and the 
residue purified by ion exchange chromatography (Dowex 50W/H+, water) to yield (±)-2-
amino-1-hydroxyethylphosphonic acid (±)-2.1 (2.092 g, 15 mmol, 50%) as crystalline solid; 94 
TLC: isopropanol/H2O/NH3(25%) = 6:3:2, Rf = 0.18. (±)-Phosphaisoserine was crystallised 
from water/ethanol to give colourless, cubic crystals; mp 273°C (decomposition). 
 
1H NMR (400.13 MHz, D2O, Mar2411/44 [KS3-002]): δ = 4.00 (td, J = 9.9 Hz, 3.3 Hz, 1H, CHP), 
3.31 (ABXP system, JAB = 13.3 Hz, JHH = 6.5 Hz, JHP = 3.3 Hz; JAB = 13.3 Hz, JHH = 9.9 Hz, JHP = 6.3 
Hz, 2H, CH2N). 
13C NMR (100.61 MHz, D2O, Mar2411/40 [KS3-002]): δ = 65.7 (d, J = 155.3 Hz, CH-P), 41.9 (d, 
J = 8.72 Hz, CH2). 
31P (162.03 MHz, D2O, Mar2411/45 [KS3-002]): δ = 15.0 (s). 
IR (ATR, [KS3-021]):  = 3138, 2837, 2659, 2578, 2270, 1628, 1538, 1076, 914 cm-1. 
Anal. calcd. for C2H8NO4P (141.05): C 17.03%, H 5.72%, N 9.93%; found: C 17.25%, H 5.48%, 
N 9.70%. 
 
9.4.3 Phthalimidoacetic acid (8.20) 
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A stirred mixture of glycine (8.19, 6.890 g, 93 mmol) and phthalic anhydride (14.050 g, 95 
mmol) was heated to 180°C. It melted. The reaction mixture was kept at that temperature 
for 10 min (or until the mixture solidifies again). On cooling the brown crystalline solid was 
crystallized from water to give pure 8.20 (17.173 g, 83 mmol, 89%) as colourless needles;95 
mp 190 - 192°C (literature: mp 192°C 95). 
 
1H NMR (400.27 MHz, d6-acetone, 4Apr1311/170 [KS3-013/1 Mutterlauge]): 11.50 (br. s, 1H, 
COOH), 7.95 - 7.87 (sym m, 4H, CHarom), 4.44 (s, 2H, CH2).  
 
9.4.4 Phthalimidoacetyl chloride (8.21) 
 
 
 
Phthalimidoacetic acid (8.20, 17.173 g, 84 mmol) was refluxed in SOCl2 (20 mL) for 1.5 h. 
Excess SOCl2 was removed under reduced pressure at room temperature and the residue 
was crystallised from hexanes/toluene to yield acid chloride 8.21 (16.910 g, 76 mmol, 90%) 
as pale yellow crystals;85 mp 80-82°C. 
 
1H NMR (400.27 MHz, CDCl3, May0511/81 [KS3-023]): 7.92 - 7.86 (m, 2H, CHarom), 7.80 -7.74 
(m, 2H, CHarom), 4.80 (s, 2H, CH2). 
13C NMR (100.61 MHz, CDCl3, May0511/80 [KS3-023] ): 169.3 (s, C=O), 166.8 (s, 2 x C=O), 
134.9 (s, 2C, CHarom), 131.84 (s, 2C, 2 x Carom), 124.2 (s, 2C, 2 x CHarom), 47.8 (s, CH2). 
IR (Si, [KS3-016]):  = 2936, 1803, 1776, 1722, 1404, 1381, 1110, 999, 939 cm-1. 
 
  
93 
 
9.4.5 Diisopropyl 1-oxo-2-phthalimidoethylphosphonate (8.22) 
 
 
Acid chloride 8.21 (16.246 g, 73 mmol) was dissolved in dry CH2Cl2 (75 mL). Triisopropyl 
phosphite (19.0 mL, 16.034 g, 77 mmol) was added and the resulting orange solution was 
stirred at room temperature for 30 min. The reaction mixture was concentrated under 
reduced pressure and the crude α-oxo-phosphonate was crystallised from 
hexanes/diisopropyl ether to give homogenous α-oxo-phosphonate 8.22 (20.677 g, 57 
mmol, 80%) as slightly yellow crystals; mp 88-90°C. 
 
1H NMR (400.13 MHz, CDCl3, May0511/91 [KS3-028B]): δ = 7.88 -7.82 (m, 2H, CHarom), 7.75 - 
7.69 (m, 2H, CHarom), 4.88 (d, J = 3.6 Hz, 2H, CH2), 4.81 (septd, J = 7.1 Hz, 6.2 Hz, 2H, 2 x OCH), 
1.38 (d, J = 6.2 Hz, 6H, 2 x CH3), 1.37 (d, J = 6.2 Hz, 6H, 2 x CH3). 
13C NMR (100.61 MHz, CDCl3, May0511/90 [KS3-028B]): δ = 204.4 (s, J = 177.5 Hz, CO), 167.5 
(s, 2C, 2 x C(O)N), 134.5 (s, 2C, 2 x CHarom), 132.3 (s, 2C, 2 x Carom), 123.8 (s, 2C, 2 x CHarom), 
74.2 (d, J = 7.3 Hz, 2C, 2 x OCH), 48.1 (d, J = 69.3 Hz, CH2), 24.3 (d, J = 3.7 Hz, 2C, 2 x CH3), 
24.0 (s, J = 4.8 Hz, 2C, 2 x CH3). 
31P NMR (161.98 MHz, CDCl3, May0511/92 [KS3-028B]): δ = -4.6 (s). 
IR (Si):  = 2983, 2935, 1779, 1723, 1468, 1411, 1387, 1263, 1100, 996 cm-1. 
Anal. calcd. for C16H20NO6P (353.31): C 54.39%, H 5.71%, N 3.96%, O 27.17%; found: C 
54.44%, H 5.63%, N 3.92%, O 26.92%. 
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9.4.6 (R)- and (±)-Diisopropyl 1-hydroxy-phthalimido-ethylphosphonate [(R)-8.23] (Method A) 
 
 
 
Synthesis of (R)-8.23: 
 
(R)-2-Methyloxazaborolidine (0.2 mL, 1M solution in dry toluene, commercial reagent) was 
added to a stirred solution of the α-oxophosphonate (8.22, 0.645 g, 1.8 mmol) in dry THF (3 
mL) under an argon atmosphere at -50°C. Borane dimethyl sulphide (1.2 mL, 1M solution in 
dry THF) was added slowly with a syringe pump (0.1 mm/min) over a period of 3 h. The 
reaction mixture was allowed to warm up to room temperature and afterwards methanol (2 
mL) was added. The solvent was evaporated under reduced pressure and the residue was 
purified by flash chromatography (ethyl acetate, Rf = 0.48) to give (R)-enantiomer of α-
hydroxyphosphonate (R)-8.23 (0.436 g, 1.2 mmol, 68%, ee = 52% by HPLC on chiral column) 
as colourless crystals. 96,70 
 
1H NMR (400.27 MHz, CDCl3, 4Jul0511/210 [KS3-063]): δ = 7.87 - 7.81 (m, 2H, 2 x CHarom), 
7.74 - 7.67 (m, 2H, 2 x CHarom), 4.82 - 4.68 (m, 2H, 2 x OCH), 4.22-4.06 (m, 2H, CH2), 4.02 - 
3.93 (m, 1H, CHP), 3.16 (br. s, 1H, OH), 1.36 (d, J = 6.2 Hz, 3H, CH3), 1.32 (d, J = 6.2 Hz, 3H, 
CH3), 1.31 (d, J = 6.3 Hz, 3H, CH3), 1.30 (d, J = 6.3 Hz, 3H, CH3). Oodelally 
13C (100.61 MHz, CDCl3, Jul2711/10 [KS3-063]): δ = 168.8 (s, 2C, C=O), 134.3 (s, 2C, CHarom), 
132.3 (s, 2C, Carom), 123.7 (s, 2C, CHarom), 72.08 (d, J = 7.3 Hz, OCH), 72.1 (d, J = 7.4 Hz, OCH) , 
66.9 (d, J = 161.7 Hz, CHP), 40.3 (d, J = 7.2 Hz, CH2), 24.33 (d, J = 2.0 Hz, CH3), 24.30 (d, J = 2.4 
Hz, CH3), 24.2 (d, J = 5.1 Hz, CH3), 24.1 (d, J = 4.8 Hz, CH3). 
31P (162.03 MHz, CDCl3, 4Jul0511/211 [KS3-063]): δ = 19.0 (s, integration: 1.00, desired 
product), 4.4 (s, integration: 0.01, phosphite). 
IR (ATR, [KS3-049]):  = 3275, 1709, 1397, 1210, 977 cm-1. 
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Anal. cald. for C16H22NO6P (355.33): C 54.08%, H 6.24%, N 3.94%, O 27.02%; found: C 54.04%, 
H 6.13%, N 3.90%, O 26.80% 
Analytical HPLC: Chiralcel OD-H, hexanes/isopropanol 90:10, (R)-enantiomer: tR = 7.29 min, 
(S)-enantiomer: tR = 8.70 min; ee 52%. 
 
Comment: The (R)-Mosher of the chiral, nonracemic -hydroxyphosphonate could not be 
prepared to determine the ee as the hydroxy group is too hindered to be esterified with (S)-
Mosher chloride even at higher temperatures (50°C) and by prolonged heating (3 d). 
However, 31P NMR spectra of the resulting reaction mixtures were used to qualitatively 
prove excess of the desired enantiomer. 
 
The two enantiomers of the racemate were separated by preparative HPLC on a chiral 
stationary phase (Chiralcel OD-H) to determine their melting points, spectra and optical 
rotations. Their spectroscopic data were identical. 
 
(R)-8.23  
[a]D
20 = - 19.7 (c 0.965, CH2Cl2) 
mp 120-122°C (isoprpanol) 
1H NMR (600.13 MHz, CDCl3, 6Sep0111/11 [KS3-040 R]): δ = 7.84 - 7.81 (m, 2H, 2 x CHarom), 
7.71 - 7.68 (m, 2H, 2 x CHarom), 4.79 - 4.69 (m, 2H, 2 x OCH), 4.18 (X part of ABXP-system, 
ddd, J = 9.7 Hz, J = 7.6 Hz, J = 3.3 Hz, 1H, CHP), 4.02 (ABXP-system, A-part:, JAB  = 14.5 Hz, J  = 
9.7 Hz, J  = 7.9 Hz; B-part: JAB = 14.5 Hz, J = 6.8 Hz, J = 3.3 Hz, 2H, CH2N), 1.35 (d, J = 6.5 Hz, 3H, 
CH3), 1.31 (d, J = 6.3 Hz, 6H, 2 x CH3), 1.28 (d, J = 6.1 Hz, 3H, CH3). 
13C (150.90 MHz, CDCl3, 6Sep011/10 [KS3-040 R]: δ = 168.7 (s, 2C, C=O), 134.3 (s, 2C, CHarom), 
132.2 (s, 2C, Carom), 123.6 (s, 2c, CHarom), 72.1 (d, J = 6.3 Hz, OCH), 72.0 (d, J = 6.6 Hz, OCH), 
66.7 (d, J = 162.1 Hz, CHP), 40.2 (d, J = 7.4 Hz, CH2N), 24.3 (d, J = 3.5 Hz, 2C, 2 x CH3), 24.13 
(d, J = 4.5 Hz, CH3), 23.06 (d, J = 4.5 Hz, CH3). 
31P (242.93 MHz, CDCl3, 6Sep0111/12 [KS3-040 R]): δ = 20.4 (s). 
IR (ATR, [KS3-040 R]): = 3266, 2980, 1708, 1397, 1209, 977 cm-1. 
 
(S)-8.23 
[a]D
20 = + 18.4 (c 1.040, CH2Cl2) 
mp 121-123°C (isopropanol) 
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Synthesis of (±)-8.23: 
 
(±)-Diisopropyl 1-hydroxy-2-phthalimidoethylphosphonate [(±)-8.23, 0.106 g, 33%] was 
prepared from -oxophosphonate 8.22 (0.321 g, 0.91 mmol) using the same method as for 
the chiral, nonracemic one except that (R)-2-methyl-oxazaborolidine was omitted.  
 
The recorded NMR spectra are identical to those of (R)-8.23. 
 
9.4.7 (R)-Diisopropyl 1-hydroxy-2-phthalimidoethylphosphonate [(R)-8.23] (Method B)  
 
 
 
(R)-2-Methyloxazaborolidine (2.2 mL, 1M solution in toluene) was added to a stirred solution 
of α-oxophosphonate 8.22 (6.540 g, 18.5 mmol) under argon atmosphere at room 
temperature. The mixture was cooled to -78°C immediately and catecholborane (2.446 g, 
20.4 mmol, 2.2 mL) was added in one portion. The reaction mixture was stored at -23°C for 5 
h and was then allowed to warm up to room temperature. It was diluted with Et2O (200 mL) 
and extracted with a saturated aqueous solution of NaHCO3 (5 x 50 mL). The organic layer 
was dried (MgSO4) and concentrated under reduced pressure. 
The crude hydroxyphosphonate was purified by flash column chromatography (ethyl 
acetate, Rf = 0.53) to yield chiral, nonracemic (R)-8.22 (5.369 g, 15.1 mmol, 82%, ee 84% by 
HPLC).70,96  
The ee could not be increased by crystallisation as the racemate crystallised slightly more 
readily and the desired (R)-enantiomer was enriched in the mother liquor.  
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9.4.8 (R)-Phosphaisoserine [(R)-2.1] 
 
 
 
A mixture of protected (R)-phosphaisoserine [(R)-8.23, 5.369 g, 15.1 mmol, ee 78%] and HCl 
(100 mL, 6M) was refluxed for 18 h. The reaction mixture was cooled and subsequently 
concentrated under reduced pressure. The residue was dried in vacuo and then dissolved in 
ammonia solution (100 mL, 25%) The resulting mixture was stirred at 50°C for 24 h to give 
(R)-2-amino-1-hydroxyethylphosphonic acid [(R)-2.1] in admixture with a phthalic acid 
derivative, possibly phthalimide. 
The solution was concentrated under reduced pressure, the residue dissolved in water (10 
mL) and extracted with ethyl acetate (3 x 20 mL). The aqueous phase was separated and 
concentrated under reduced pressure. The crude product was applied to a column filled with 
Dowex 50W/H+ (water as eluent: TLC: Rf = 0.19, iPrOH/H2O/NH3(25%) = 6:3:2, ninhydrin 
reagent for detection) to give (R)-phosphaisoserine [(R)-2.1. 1.833 g, 13.0 mmol, 86%]; ee 
will have to be determined. 
 
Recorded NMR spectra and melting point were identical to that of (±)-2.1. 
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10. Summary 
 
Organophosphonates, compounds containing a direct P-C bond, play an important role in 
medicine agriculture and industry. They can be mineralised and used as an additional or sole 
phosphorus source by microorganisms including some pathogens but not vertebrates.  
Their biodegradation is of crucial interest as it helps to understand their role in the global 
phosphorus redox cycle and to get a closer insight into their mode of action. Much work has 
already been done to clarify the biosynthesis of several phosphonates, showing remarkable 
and unexpected results. However, only little is known about their biodegradation. 
 
In the course of my master thesis I have synthesised several phosphonates which will be 
used to study the biodegradation of the antibiotic fosfomycin and 2-amino-1-
hydroxyethylphosphonic acid, a cell component of amoeba. 
The 3,3,3-trifluoro analogue of (1R*,2R*)-1,2-dihydroxypropylphosphonic acid was 
synthesised using trifluoroacetaldehyde hydrate as starting material which was converted to 
the corresponding cyanohydrine. Its hydroxyl group was TIPS-protected and the resulting -
silyloxynitrile was reduced with DIBAl-H to give racemic 3,3,3-trifluoro-2-
triisopropylsilyloxypropanal. Then, diethyl trimethylsilyl phosphite was added to the 
carbonyl group to form a P-C bond. The two resulting diastereomers were separated by flash 
chromatography and only the one with (1R*,2R*)-configuration was completely deprotected 
to give the desired compound as a racemate. Its synthesis could be accomplished by a six 
step reaction sequence with an overall yield of 6%.  
Furthermore, (±)- and (S)-1-hydroxy-2-oxopropylphosphonic acid were synthesised in three 
and five steps, respectively. Starting from methacroleine, racemic dimethyl 1-hydroxy-2-
methyl-2-propenylphosphonate was prepared. Its two enantiomers were obtained by 
chemical resolution with Noe’s reagents. The racemate and the (S)-enantiomer of this -
hydroxyphosphonate were converted to the sodium salts of the acids and ozonolysed to give 
-oxophosphonates. It was found by measuring the H/D exchange at C-1 by 1H NMR 
spectroscopy and the optical rotation that racemisation at neutral pH in 24 h is negligible.  
A new synthetic route to (±)-2-amino-1-hydroxyethylphosphonic acid comprising two steps 
was optimised. Epoxidation of commercially available vinylphosphonic acid followed by 
ammonolysis of the epoxide yielded 40% of the target compound.  
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Finally, (R)-2-amino-1-hydroxyethylphosphonic acid was synthesised in six steps with an ee 
of 81% and an overall yield of 49%. The starting material, phthalimidoacetic acid, was 
prepared from glycine and was converted to the acid chloride which was subsequently 
reacted with triisopropyl phosphite. The key step of this synthesis was enantioselective 
reduction of the thus formed -oxophosphonate using catecholborane and (R)-2-
methyloxazaborolidine as catalyst. Removal of the protective groups finished the synthesis 
of the compound needed in g quantities for biodegradative studies. 
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11. Zusammenfassung 
 
Organophosphonate, Verbindungen mit einer direkten P-C-Bindung, spielen in der Medizin, 
Landwirtschaft und Industrie eine wichtige Rolle. Sie können von Mikroorganismen, einige 
pathogene eingeschlossen, nicht aber von Wirbeltieren, mineralisiert und als zusätzliche 
oder alleinige Phosphorquelle verwendet werden. Ihr biologischer Abbau ist von 
entscheidender Bedeutung, da er hilft, ihre Rolle im globalen Phosphor-Redox-Zyklus zu 
verstehen und ein tieferes Verständnis ihrer Wirkungweise zu gewinnen. Verschiedene 
Arbeitsgruppen haben sich bereits mit der Aufklärung der Biosynthese einiger spezieller 
Phosphonate beschäftigt und dabei bemerkenswerte und gleichzeitig erstaunliche 
Ergebnisse erhalten. Die Biodegradation von Phosphonsäuren ist hingegen noch immer 
kaum erforscht. 
 
Im Rahmen meiner Masterarbeit habe ich verschiedene Phosphonate synthetisiert, die bei 
Studien zur Aufklärung der Biodegradation von Fosfomycin und der 2-Amino-1-
Hhydroxyethylphosphonsäure eingesetzt werden sollen. 
Das 3,3,3-Trifluor-substituierte Analogon der (1R*,2R*)-1,2-Dihydroxypropylphosphonsäure 
wurde ausgehend von Trifluoracetaldehyd-Hydrat synthetisiert, das in das Cyanhydrin 
überführt wurde. Seine Hydroxygruppe wurde TIPS-geschützt und das resultierende -
silyloxy-substituierte Nitril wurde mit DIBAl-H zum Aldehyd reduziert. Dann wurde 
Diethyltrimmethylsilylphosphit an die Carbonylgruppe addiert, um die P-C-Bindung zu 
bilden. Die beiden resultierenden Diastereomere wurden mittels Flash-Chromatography 
getrennt und vollständig deblockiert. Die gewünschte Verbindung entstand als Racemat, 
dessen Synthese in sechs Schritten in einer Gesamtausbeute von 6% gelang.  
Des Weiteren wurde racemische und enantiomerenreine (S)-1-Hydroxy-2-
oxopropylphosphonsäure in drei bzw. fünf Schritten synthetisiert. Ausgehend von  
Methancrolein wurde racemisches Dimethyl 1-hydroxy-2-methyl-2-propenylphoshonat 
hergestellt. Seine beiden Enantiomere wurden durch chemische Racematspaltung mit Noe 
Reagentien erhalten. Das Racemat und das (S)-Enantiomer dieses -Hydroxyphosphonats 
wurden in die Natriumsalze der Säuren überführt, die mittels Ozonolyse die -
Oxophosphonate lieferten. Durch Messung des H/D-Austausches am C-1 und des Drehwerts 
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wurde gefunden, dass die Racemisierung bei neutralem pH innerhalb von 24 h unbedeutend 
ist.  
Darüber hinaus wurde eine neue zweistufige Synthese für (±)-2-Amino-1-
hydroxyethylphosphonsäure ausgehend von kommerziell erhältlicher Vinylphosphonsäure 
optimiert. Diese wurde epoxidiert und das entstandene Epoxid anschließend mit Ammoniak 
regioselektiv geöffnet. Dies liefert die gewünschte Zielverbindung mit einer 40%igen 
Ausbeute. 
Schließlich wurde (R)-2-Amino-1-hydroxyethylphosphonsäure in einer sechsstufigen 
Synthesesequenz mit einer Gesamtausbeute von 49% und einem ee von 81% hergestellt. 
Das Ausgangmaterial, die Phthalimidoessigsäure, die aus Glycin hergestellt und in das 
Säurechlorid überführt wurde, wurde mit Triisopropylphosphit umgesetzt. Der 
Schlüsselschritt dieser Synthese ist die enantioselective Reduktion des α-Oxophosphonates 
mit Catecholboran und (R)-2-Methyloxazaborolidin als Katalysator. Abspaltung der 
Schutzgruppen schloss die Synthese der Verbindung, die in Gramm-Mengen für 
Abbaustudien benötigt wird, ab. 
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